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Abstract 
Chapter 1. Use of boron as a pharmacophore is as growing but still underdeveloped 
strategy for expanding chemical space in biomedical research. In addition to more 
established methods of incorporating boron in drug development, an attractive and 
emerging method of introducing boron into biologically active compounds is through 
boron-nitrogen containing heterocycles. In particular, the Liu group has focused on 
exploring the interactions of monocyclic 1,2-azaborines in biological space. In order to 
install complicated chemical functionality needed for further studies, methods for late 
stage functionalization of 1,2-azaborines must be developed. Described herein is a 
method for functionalizing 1,2-azaborine at the C3- and C5-positions, with bromine and 
iodine handles, respectively. 
Chapter 2. Described is the application of the turbo Grignard reaction to 1,2-azaborines 
bearing a B–Cl bond. The reaction utilizes iPrMgCl·LiCl to form aryl carbon 
nucleophiles and is tolerant of sensitive functional groups such as nitriles and esters. 
Development of the reaction obviates the need to use toxic organotin reagents to install 
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Towards a Tetra-Orthogonally Reactive Azaborine: Functionalizing the C3- and 
C5-Postions of 1,2-Azaborines with Chemically Distinct Handles 
1.1 Introduction 
1.1.1 Boron Containing Compounds in Medicinal Chemistry 
Boron is the fifth element on the periodic table, and it occupies a place 
immediately before carbon, nitrogen, and oxygen. Unlike its ubiquitous neighbors, 
however, boron is not widely found in the chemical framework of biology. In fact, boron 
is relatively rare not just on earth but in the universe at large (Table 1.1). While carbon, 
nitrogen, oxygen, and neon have an estimated fractional atomic abundance of 9.3x10-4 by 
number, lithium, beryllium, and boron only have an abundance of 3.3x10-9 by number. 
The relative scarcity of these lighter elements, a difference of five orders of magnitude, 
can be understood as a direct result of their unique manner of formation and their 
instability at the high temperatures of stellar environments.1 
 
                                                 
1 (a) Suess, H. E.; Urey, H. C. Abundances of the Elements. Rev. Mod. Phys. 1956, 28, 53–74. (b) Suess, H. 
E. V. M. Goldschmidt and Origin of the Universe. Appl. Geochem. 1988, 3, 385–391. (c) Burbidge, E. M.; 
Burbidge, G. R.; Fowler, W. A.; Hoyle, F. Synthesis of the Elements in the Stars. Rev. Mod. Phys. 1957, 
29, 547–650. (c) Anderson, D. L. Chemical Composition of the Mantle in Theory of the Earth; Blackwell 
Scientific Publications: Boston, 1989, 147–177. 
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While most elements lighter than iron are formed in the high temperature 
environment immediately following the big bang or in the interior of stars, more fragile 
elements, such as boron, are not able to survive such environments.2a It is believed that 
boron, in addition to beryllium and lithium, is formed by cosmic ray interactions in the 
interstellar medium. This process, known as “cosmic ray spallation,” produces lithium, 
beryllium, and boron via energetic collisions between carbon, nitrogen, or oxygen and 
protons, alpha particles, or helium nuclei.2 These interactions are of lower energy and at 
lower density than stellar nucleosynthesis, and as a result are far less prolific. 
Consequently, the abundance of these three elements in the universe is much lower than 
the elements directly succeeding them.  
Understandably, boron is not widely found in biological systems. While boron as 
boric acid is essential in trace amounts to 
the health of plants, its incorporation into 
natural products is fairly rare.3 The first 
natural product known to contain boron, 
boromycin (Figure 1.1), was discovered 
in 1967 and characterized in 1971.3b,4 As 
in boromycin, all boron-containing 
                                                 
2 (a) Prantzos, N.; Casse, M.; Vangioni-Flam, E. Production and Evolution of LiBeB Isotopes in the 
Galaxy. ApJ. 1993, 403, 630–643. (b) Ramaty, R.; Kozlovsky, B.; Lingenfelter. R. E.; Reeves, H. Light 
Elements and Cosmic Rays in the Early Galaxy. ApJ. 1997, 488, 730–748. (c) Reeves, H.; Fowler, W. A.; 
Hoyle, F. Galactic Cosmic Ray Origin of Li, Be, and B in Stars. Nature 1970, 226, 727–729. 
3 (a) Yoshinari, A.; Takano, J. Insights into the Mechanisms Underlying Boron Homeostasis in Plants. 
Front. Plant Sci. 2017, 8, 1951 (b) Uluisik, I.; Karakaya, H. C.; Koc, A. The Importance of Boron in 
Biological Systems. J. Trace Elem. Med. Biol. 2018, 45, 156–162. (c) Miwa, K.; Fujiwara, T. Boron 
Transport in Plants: Co-ordinated Regulation of Transporters. Annals of Botonay 2010, 105, 1103–108. 
4 (a) Dunitz, J. D.; Hawley, D. M.; Miklos, D.; White, D. N. J.; Berlin, Y.; Marusic, R.; Prelog, V. Structure 
of Boromycin. Helvetica Chimica Acta 1971, 54, 1709–1713. (b) Chen, T. S. S.; Chang, C.-J.; Floss, H. G. 
On the Biosynthesis of Boromycin. J. Org. Chem. 1981, 46, 2661–2665. 
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natural products feature boron bound exclusively to oxygen; no known natural products 
contain boron–carbon bonds.5 
In part due to its relative absence in natural products, boron-containing drugs have 
not been widely used in medicinal chemistry. To date, only five drugs containing boron 
have been approved for commercial use by the USFDA (Figure 1.2).. Bortezomib was 
the first boron containing drug (2003) and is a serine protease inhibitor approved for 
treatment of multiple myeloma.6 Following bortezomib’s approval, it was another ten 
years before tavaborole was approved as a topical antifungal treatment.7 
 
In 2015, ixazomib was approved for treatment of multiple myeloma as well. Like 
bortezomib, it also acts as a protease inhibitor. Unlike bortezomib, ixazomib can be orally 
administered, which is due to the hydrophilic boronic ester formed with citric acid.8 
Crisaborole was approved as a topical phosphodiesterase inhibitor for treatment of atopic 
                                                 
5 Diaz, D. B.; Yudin, A. K; The Versatility of Boron in Biological Target Engagement. Nat. Chem. 2017, 9, 
731–742. 
6 Paramore, A.; Frantz, S. Bortezomib. Nat. Rev. Drug Discov. 2003, 2, 611–612. 
7 Markham, A. Tavaborole: First Global Approval. Drugs 2014, 74, 1555–1558. 
8 Shirley, M.; Ixazomib: First Global Approval. Drugs 2016, 76, 405–411. 
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dermatitis in 2016.9 The following year vaborbactam, a β-lactamase inhibitor, was 
approved in combination with the carbapenem antibiotic meropenem as a treatment 
against carbapenem-resistant bacteria.10 
In recent years the use of boron in the development of drugs and biologically-
active molecules has increased dramatically.5,11 Because of its unique electronic 
properties and versatile molecular geometry, which arise from a vacant p-orbital, boron 
possesses unique reactivity that is not found elsewhere in the arsenal of medicinal 
chemistry. Because of its absence in biology, there are few sources of natural inspiration 
from which drug design approaches can be drawn, and novel methods of incorporating 
boron into biologically-active compounds must be explored. 
The ability of boron to exist as both tri-substituted, charge neutral species and 
tetra-substituted, negatively charged species is essential to the unique target engagement 
of boronic acid-containing compounds.5 For many of these compounds, serine proteases 
are the most common target of inhibition.5 Natural protease substrates can be used as 
inspiration for their inhibitors; for most boronic acid inhibitors, the most significant 
change is the replacement of a scissile amide bond with a boronic acid moiety.5,11 
Boronic acids first gained attention as potential enzymatic inhibitors in the late 
1960s and early 1970s. Several early studies found that boronic acids acted as inhibitors 
of subtilisin and chymotrypsin proteolytic enzymes, and the structure of the inhibitor-
                                                 
9 Paton, D. M. Crisaborole: Phosphodiesterase Inhibitor for Treatment of Atopic Dermatitis. Drugs Today 
2017, 53, 239–245. 
10 Lee, Y.; Kim, J.; Trinh, S. Meropenem–Vaborbactam (VabomereTM): Another Option for Carbapenem-
Resistant Enterobacteriaceae. P .T. 2019, 44, 110–113. 
11Kahlert, J.; Austin, C. J. D.; Kassiou, M.; Rendina, L. M. The Fifth Element in Drug Design: Boron in 
Medicinal Chemistry. Aust. J. Chem. 2013, 66, 1118–1123. 
5 
 
enzyme complex was posited to be a tetra-coordinate boronate species.12 Further 
crystallographic studies of two boronic acid inhibitors of subtilisin confirmed the 
presence of a tetra-coordinate boron bound covalently to oxygen of a serine residue in the 
enzyme active site.13 
An example of typical inhibition of proteases by boronic acid containing 
compounds has been provided in Scheme 1.1. In this case, the boronic acid forms a 
cyclic diester with glycerol, which was present in enzyme preparation. After association 
with the inhibitor, the catalytic serine residue covalently captures the boron electrophile. 
The boron undergoes a transition from the tri-coordinate boronic ester to a tetra-
coordinate borate species. While the tetrahedral transition state of the natural enzyme 
substrate is unstable and leads to amide scission, the stability of this anionic boron 
species arrests the mechanism of the enzyme, leading to target inhibition.5,14  
 
                                                 
12 (a) Antonov, V. K.; Ivanina, T. V. n-Alkylboronic Acids as Bifunctional Reversible Inhibitors of α-
Chymotrypsin. FEBS Lett. 1970, 7, 23–25. (b) Koehler, K. A.; Lienhard, G. E. 2-Phenylethaneboronic 
Acid, a Possible Transition State Analog for Chymotrypsin. Biochemistry 1971, 10, 2477–2483. (c) Philipp, 
M.; Bender, M. L. Inhibition of Serine Proteases by Arylboronic Acids. Proc. Natl. Acad. Sci. 1978, 68, 
478–480. (d) Lindquist, R. N.; Terry, C. Inhibition of Subtilisin by Boronic Acids, Potential Analogs of 
Tetrahedral Reaction Intermediates.  Arch. Biochem. Biophys. 1974, 160, 135–144. 
13 Matthews, D. A.; Alden, R. A.; Birktoff, J. J.; Freer, S. T.; Kraut, J. X-ray Crystallographic Study of 
Boronic Acid Adducts with Subtilisin BPN’ (Novo). J. Biol. Chem. 1975, 250, 7120–7126. 
14 (a) Lei, J.; Hansen, G.; Nitsche, C.; Klein, C. D.; Hilgenfeld, R. Crystal Structure of Zika Virus NS2B-
NS3 Protease in Complex with a Boronate Inhibitor. Science 2016, 353, 503–505. (b) Nitsche, C.; Zhang, 
L.; Weigel, L. F.; Schilz, J.; Graf, D.; Bartenschlager R.; Hilgenfeld, R.; Klein, C. D. Peptide–Boronic Acid 




While most research of boronic acid-containing compounds and medicinal 
chemistry has focused on their role as protease inhibitors, they have also been utilized as 
inhibitors of enzymes, such as proteasomes,15 arginases,16 and β-lactamases,17 among 
others. Like protease inhibitors, many of these boronic acid inhibitors utilize boron’s 
ability to form stable bonds with nucleophilic moieties to arrest enzymatic activity.5,14 
Boron’s unique electronic properties can also be observed in its ability to form 
boron clusters.18b Boron can form compounds with stable, three-center two-electron 
boron–hydrogen–boron bonds, the most simple of which is diborane (1.2). Boron and 
hydrogen can also produce a number of stable three-dimensional boron clusters of the 
general formula BnHn2-. Carboranes are a similar class of clusters in which two of the B–
H bonds are typically replaced with the isoelectronic C–H+ bonds, giving the general 
formula C2BnHn+2 (Figure 1.3). The most commonly used carboranes in medicinal 
chemistry are the closo-C2B10H12 (1.3-1.5) carboranes and the nido-C2B9H10- (1.6-1.8) 
carboranes.18b These clusters do not possess classic two-center two-electron bonds, but 
instead feature electrons delocalized throughout the molecule. As such, carboranes can be 
described as having three-dimensional aromaticity.18a As a result of this unique mode of 
bonding, boron and carbon atoms are hexacoordinate, though vertices simply represent 
                                                 
15 (a) Richardson, P. G.; et al. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. N. Engl. 
J. Med. 2003, 348, 2609–2617. (b) Piva, R.; et al. CEP–18770: A Novel, Orally Active Proteasome 
Inhibitor with a Tumor–Selective Pharmacological Profile Competitive with Bortezomib. Blood 2008, 111, 
2765–2775(c) Kumar, S. J.; et al. Safety and Tolerability of Ixazomib, an Oral Protease Inhibitor, in 
Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple 
Myeloma: An Open Label Phase 1/2 Study. Lancet 2014, 15, 1503–1512. 
16 (a) Baggio, R.; et al. Inhibition of Mn2+ 2-Arginase by Borates Leads to the Design of a Transition State 
Analogue Inhibitor, 2(S)-Amino-6-boronohexanoic Acid. J. Am. Chem. Soc. 1997, 119, 8107–8108. (b) 
Cox, J. D.; Kim, N. N.; Traish, A. M.; Christianson, D. W. Arginase Boronic-acid Complexes Highlights a 
Physiological Role in Erectile Dysfunction. Nat. Struct. Biol. 1999, 6, 1043–1047. 
17 (a) Weston, G. S.; Blázquez, J.; Baquero, F.; Shoichet, B. K. Structure-Based Enhancement of Boronic 
Acid-Based Inhibitors of AmpC β-Lactamase. J. Med. Chem. 1998, 41, 4577–4586. (b) Hecker, S. J.; et al. 
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine 
Carbapenemases. J. Med. Chem. 2015, 58, 3682–3692. 
7 
 
connections between atoms rather than electron pairs as in traditional bonding 
convention. Another important distinction between C–H and B–H bonds is in the 
behavior of bound hydrogen atom: B–H bonds are hydridic in nature while the C–H 
bonds are protic.18 
 
                                                 
18 (a) Issa, F.; Kassiou, M.; Rendina, L. M. Boron in Drug Discovery: Carboranes as Unique 
Pharmacophores in Biologically Active Compounds. Chem. Rev. 2011, 111, 5701–5722. (b) Leśniowsi, S. 
J. Challenges and Opportunities for the Application of Boron Clusters in Drug Design. J. Med. Chem. 
2016, 59, 7738–7758. (c) Stockmann, P.; Gozzi, M.; Kuhnert, R.; Sárosi, M. B.; Hey-Hawkins, E. New 
Keys for Old Locks: Carborane-Containing Drugs as Platforms for Mechanism-Based Therapies. Chem. 
Soc. Rev. 2019, 48, 3497–3512. 
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These unique compounds have found widespread use in medicinal chemistry. 
Their first use as therapeutic agents came in 1968 when Hiroshi Hatanaka used sodium 
borocaptate (1.9) as a boron source for boron-neutron capture therapy (BNCT).19 Used to 
treat malignant brain tumors, BNCT requires the accumulation of 10B in tumor cells. 
Tumor cells are then bombarded by neutrons, causing the boron to undergo a fission 
event and produce lithium-7 and high energy alpha particles. Alpha particles have a short 
lifetime, travelling less than <10 µm, and thus only destroy cells which have 10B atoms in 
them.19 Because of the high concentration of boron per molecule, as well as their stability 
in biological environments, boron clusters are attractive candidates for this therapy.18 To 
increase uptake by tumors and limit concentration in healthy tissue, boron clusters have 
been attached to a number of different delivery agents for study as boron sources for 
BNCT. These delivery agents include sugars,20 polypeptides21 and nucleosides22 among 
many others. A more comprehensive list can be found in a recent review by Barth et al.23 
Carboranes have been the subject of increased investigation as a way to introduce 
new chemical diversity in biologically-active compounds. Incorporation of lipophilic 
carboranes offers an attractive avenue for modulating the compound’s pharmacokinetic 
properties and increasing efficacy in vivo. The utility of carboranes can be illustrated by 
compound 1.10. This molecule was tested as a vitamin D receptor agonist with potency  
                                                 
19 Nedunchezhian, K.; Aswath, N.; Thiruppathy, M.; Thirugnanamurthy, S. Boron Neutron Capture 
Therapy: A Literature Review. J. Clin. Diagn. Res. 2016, 10, ZE01–ZE04. 
20 Lai, C.-H.; Lin, Y.-C.; Chou, F.-I.; Liang, C.-F.; Lin, E.-W.; Chuang, Y.-J.; Lin, C.-C. Design of 
Multivalent Galactosyl Carborane as a Targeting Specific Agent for Potential Application to Boron 
Neutron Capture Therapy. Chem. Commun. 2018, 48, 612–614. 
21 Mier, W.; Gabel, D.; Haberkorn, U.; Eisenhut, M. Conjugation of the closo-Borane 
Mercaptoundecahydrododecaborate (BSH) to a Tumor Selective Peptide. Z. Anorg. Allg. Chem. 2004, 630, 
1258–1262. 
22 Soloway, A. H.; Zhou, J.-C.; Rong, F.-G.; Lunato, A. J.; Ives, D. H.; Barth, R. F.; Anisuzzaman, A. K. 
M.; Barth, C. D.; Barnum, B. A. Identification, Development, Synthesis and Evaluation of Boron-
Containing Nucleosides for Boron Neutron Capture Therapy. J. Organomet. Chem. 1999, 581, 150–155. 
23 Barth, R. F.; Mi, P.; Yang, W. Boron Delivery Agents for Boron Neutron Capture Therapy. Cancer 




comparable to the natural substrate, calcitriol (1.11). Interestingly, 1.10 did not exhibit 
any of the hypercalcemia typically associated with calcitriol.24 Carboranes have also been 
employed in developing longer lasting lidocaine derivatives (1.12),25 as well as 
developing novel HIV protease inhibitors (1.13),26 CNS active antidepressants (1.14),27 
and other biologically active molecules.18 
                                                 
24 Otero, R.; Soeane, S.; Sigüeiro, R.; Belorusova, A. Y.; Maestro, M. A.; Pérez-Fernández, R.; Rochel, N.; 
Mouriño, A. Carborane-Based Design of a Potent Vitamin D Receptor Agonist. Chem Sci. 2016, 7, 1033–
1037. 
25 Kracke, G. R.; VanGordon, M. R.; Sevryugina, T. V.; Kueffer, P. J.; Kabytaev, K.; Jalisatgi, S. 
S.;Hawthorne, M. F. Carborane-Derived Loval Anesthetics Are Isomer Dependent. ChemMedChem 2015, 
10, 62–67. 
26 (a) Kubát, P.; Lang, K.; Cígler, P.; Kožíšek, M.; Matĕjíček, P.; Janda, P.; Zelinger, Z.; Procházka, K.; 
Král, V. Tetraphenylporphyrin-cobalt(III) Bis(1,2-dicarbollide) Conjugates: From the Solution 
Characteristics to Inhibition of HIV Protease. J. Phys. Chem. B. 2007, 111, 4539–4546. (b) Cigler, P.; et al. 
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In addition to these two more established methods of incorporating boron in drug 
development, an attractive and emerging method of introducing boron into biologically 
active compounds is through boron-nitrogen containing heterocycles.5 Boron’s electron 
deficient nature, when paired with electron rich nitrogen, allows for the formation of 
compounds that are isoelectronic and isostructural to carbon-based compounds. This 
particular use of the unique electronic properties of boron will be discussed thoroughly 
throughout the remainder of the chapter. 
1.1.2 BN/CC Isosterism and Azaborines 
The concept of isosterism was first introduced in 1919 by Irving Langmuir who 
defined the term as molecules that contain the same number of atoms and electrons, 
different only in the charges on the nuclei of the constituent atoms.28 In his initial 
publication, Langmuir noted the similarities in physical properties among sets of 
isosteres, most of which were inorganic compounds. In the 100 years since its initial 
development, the concept of isosterism has become a practical strategy utilized in organic 
chemistry.29 In particular, isosteres can be utilized in organic chemistry as a way of 
introducing chemical diversity as well as modulating chemical properties of molecules 
while leaving their structural framework largely unchanged. 
This concept of isosterism can be illustrated by the concept of BN/CC isosterism, 
in which a carbon-carbon unit in a molecule is replaced with a boron-nitrogen unit. One 
of the simplest examples of BN/CC isosterism is the relationship between a carbon–
                                                                                                                                                 
From Nonpeptide Toward Noncarbon Protease Inhibitors: Metallocarboranes as Specific and Potent 
Inhibitors of HIV Protease. PNAS 2005, 102, 15394–15399 
27 Wilkinson, S. M.; Gunosewoyo, H.; Barron, M. L.; Boucher, A.; McDonnell, M.; Turner, P.; Morrison, 
D. E.; Bennett, M. R.; McGregor, I. S.; Rendina, L. M.; Kassiou, M. The First CNS-Active Carborane: A 
Novel P2X7 Receptor Agonist with Antidepressant Activity. ACS Chem. Neurosci. 2014, 5, 335-339. 
28 Langmuir, I. Isomorphism, Isosterism, and Covalence. J. Am. Chem. Soc. 1919, 41, 1543–1559. 
29 Lima, L. M.; Barreiro, E. J. Bioisosterism: A Useful Strategy for Molecular Modification and Drug 
Design. Curr. Med. Chem. 2005, 12, 23–49. 
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carbon double bond and nitrogen–boron double bond. Both units contain two atoms and 
eight valence electrons. In the case of the carbon–carbon double bond, both carbons have 
four valence electrons and are charge neutral. In the case of the nitrogen–boron double 
bond, nitrogen possesses five valence electrons while boron possesses three. As a result 
of this electronic distribution, a nitrogen–boron double bond also has eight valence 
electrons, but the nitrogen is positively charged while the boron is negatively charged.  
While Langmuir was preoccupied with identifying similarities in the properties of 
isosteres, it is the difference in properties between the CC unit and the BN unit that make 
BN/CC isosterism noteworthy. Ethene (1.15, bp –104 ºC) is a volatile gas under standard 
conditions, and has a bond dissociation energy of 174.1 kcal mol-1, 65.0 kcal mol-1 of 
which can be attributed to its π-bond.30 Due to the symmetric nature of the molecule, 
ethene has no effective dipole moment.31 Ethene’s BN isostere, aminoborane (1.16), 
lacks the symmetry of ethene. As a result, the properties of aminoborane are markedly 
different than those of ethene. Aminoborane has a dipole moment of 1.84 D, is generally 
unstable, and prefers to form cyclic oligomers and polymers.32 Additionally, the π 
contribution to the bond strength of amino borane is less than that of ethene at only 29.9 
kcal mol-1 while the σ contribution is comparable at 109.8 kcal mol-1.33 
 
                                                 
30 Blanksby, S. J.; Ellison, G. B. Bond Dissociation Energies of Organic Molecules. Acc. Chem. Res. 2003, 
36, 255–263. 
31 Pritchard, R. H; Kern, C. W. Bond Moments in the Two-Carbon Series Ethane, Ethylene, and Acetylene. 
J. Am. Chem. Soc. 1969, 91, 1631–1635. 
32 Sugie, M.; Takeo, H.; Matsumura, C. Microwave Spectrum of Aminoborane BH2NH2. Chem. Phys. Lett. 
1979, 64, 573–575. 




 Of the applications of BN/CC isosterism, none have received more attention than 
the substitution of C–C double bonds with B–N in aromatic systems. A number of BN-
arenes have been investigated,34 the simplest amongst them being monocyclic azaborines. 
                                                 
34 For Selected Reviews, see: (a) Boset, M. J. D.; Piers, W. E. B–N as a C–C Substitute in Aromatic 
Systems. Can. J. Chem. 2009, 87, 8–29. (b) Abbey, E. R.; Liu, S.-Y. BN Isosteres of Indole. Org. Biomol. 
Chem. 2013, 11, 2060–2069. (c) Bélanger-Chabor, G.; Braunschweig, H.; Roy, D. K. Recent 
Developments in Azaborinine Chemistry.  Eur. J. Inorg. Chem. 2017, 4353–4368. (d) Giustra, Z. X.; Liu, 
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1,2-azaborines are BN isosteres of benzene in which a C–C double bond is replaced with 
a B–N single bond. While three monocyclic azaborine structural isomers can exist (1.18-
1.20), 1,2-azaborines are the only among them that contain a direct B–N bond. 1,2-
dihydro-1,2-azaborine (1.18), like its CC counterpart benzene, is aromatic with a 
calculated resonance stabilization energy of 19.6 kcal mol-1.35 Unlike benzene, 1,2-
dihydro-1,2-azaborine has a dipole moment of 2.154 D36 and has a protic N–H37 bond 
which has been shown to act as a hydrogen bond donor.38 
The differences between azaborines and benzene allow for modulation of the 
properties of chemical structures by incorporating azaborines in place of benzene rings. 
In particular, the polarity and ability to engage in hydrogen bonding of 1,2-azaborine can 
be beneficial in medicinal chemistry, as this allows for changes to be made to the 
solubility and target engagement mechanics of biologically-active compounds. By 
incorporating azaborines into drug like compounds, these properties can be tuned to 
affect pharmacokinetic behavior.   
                                                                                                                                                 
S.-Y. The State of the Art in Azaborine Chemistry: New Synthetic Methods and Applications. J. Am. 
Chem. Soc. 2018, 140, 1184–1194. (e) McConnell C. R.; Liu, S.-Y. Late-Stage Functionalization of BN-
Heterocycles. Chem. Soc. Rev. 2019, 48, 3436–3453. 
35 Campbell, P. G.; Abbey, E. R.; Neiner, D.; Grant, D. J.; Dixon, D. A.; Liu, S.-Y. Resonance Stabilization 
Energy of 1,2-Azaborines: A Quantitative Experimental Study by Reaction Calorimetry. J. Am. Chem. Soc. 
2010, 132, 18048–18050. 
36 Chrostoswka, A.; Xu, S.; Lamm, A. N.; Mazière, A.; Weber, C. D.; Dargelos, A.; Baylère, P.; Graciaa, 
A.; Liu, S.-Y. UV-Photoelectron Spectroscopy of 1,2- and 1,3-Azaborines: A Combined Experimental and 
Computational Electronic Structure Analysis. J. Am. Chem. Soc. 2012, 134, 10279–10285. 
37 Marwitz, A. J. V.; Matus, M. H.; Zakharov, L. N.; Dixon, D. A.; Liu, S.-Y. A Hybrid Organic/Inorganic 
Benzene.  Angew. Chem. Int. Ed. 2009, 48, 973-977. 
38 Zhao, P.; Nettleton, D. O.; Karki, R. G.; Zécri, F. J.; Liu, S.-Y. Medicinal Chemistry Profiling of 




1.2.1 BN/CC Isosterism in Biological Space 
Drawing from Langmuir’s initial observations that isosteric compounds shared 
similar properties, the concept of bioisosterism was first expressed in 1951 by Friedman 
as compounds “that fit the broadest definition for isosteres and have the same type of 
biological activity.”39 Bioisosterism is one approach used by medicinal chemists to 
change the chemical properties of lead compounds while maintaining desired 
pharmacological activity.40 As will be demonstrated for the case of BN/CC isosterism, 
replacement of carbonaceous arenes with their BN isosteres can help a medicinal chemist 
tweak properties such as solubility and lipophilicity or even change the dynamics of 
binding within the pocket of a target protein.  
 The first example of BN heterocycles investigated for their biological activity 
came shortly after Dewar’s pioneering synthesis of BN isosteres of polycyclic arenes. In 
                                                 
39 Friedman, H. L. Influence of Isosteric Replacement of Biological Activity. NASNRS 1951, 206, 295–358. 




1964, Dewar prepared a number of polycyclic 10,9-Borazarophenanthrenes (1.21-1.23) 
and 2,1-Borazaronaphthalenes (1.24-1.25) as potential candidates for BNCT boron 
sources (Figure 1.6). Though he succeeded in creating BN isosteres that had improved 
aqueous solubility relative to their carbonaceous counterparts, the compounds showed a 
preference for concentrating in healthy brain tissue instead of tumors of cancerous mice 
and killed their hosts immediately upon administration.41  
Over a decade after Dewar’s initial attempts at 
using BN heterocycles as BNCT boron sources, 
polycyclic diazaborines were studied as antibacterial 
agents. Diazaborines were found to inhibit biosynthesis 
of lipopolysaccharide, which is an integral part of the 
outer membrane of Gram-negative bacteria.42 In 1981, compound 1.26 was found to have 
antibacterial activity against E. coli and Salmonella typhimurium with minimum 
inhibitory concentration values of 1.25 and 2.5 µg/mL, respectively.42  
Crystallographic analysis inside the binding pocket of E. coli enoyl reductase, an 
enzyme involved in fatty acid biosynthesis, revealed a covalent interaction between the 
boron of 1.26 and the 2’ hydroxyl of a nicotinamide adenine dinucleotide (NAD+) ribose 
present in the enzyme.43 Much like boronic acid containing serine protease inhibitors, this 
covalent interaction results in a tetracoordinate boron species and provides a clear 
explanation for the inhibitory properties of diazaborines. Replacement of the BN unit in 
                                                 
41 Dewar, M. J. S.; Hashmall, J.; Kuba, V. P. New Heterocyclic Boron Compounds. XIX. Water-Soluble 
Derivatives of 10,9-Borazarophenanthrenes and 2,1-Borazarophenanthrenes as Potential Agents for 
Neutron Capture Therapy. J. Org. Chem. 1964, 29, 1755–1757. 
42 Hogenauer, G.; Woisetschlager, M. A Diazaborine Derivative Inhibits Lipopolysaccharide Biosynthesis. 
Nature 1981, 293, 662–664 
43 Baldock, C.; Rafferty, J. B.; Sedelnikova, S. E.; Baker, P. J.; Stuitje, A. R.; Slabas A. R.; Hawkes, T. R.; 
Rice, D. W. A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase. Science 
1996, 274, 2107–2110. 
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the diazaborine with the isosteric CC unit showed no biological activity, and a number of 
polycyclic diazaborine compounds have shown similar antibacterial potency.44 
In 2015, Vlasceanu et al. reported the pharmacokinetic profile of a number of 
different borazaronanphthyl-containing compounds as PDE10A inhibitors. PDE10A 
inhibition has gained interest as treatment for Parkinson’s Disease, Huntington’s Disease, 
schizophrenia, and obsessive compulsive disorder.45 In all cases, the borazaronaphthyl-
containing compounds (1.28a-f) were more active inhibitors than their carbonaceous 
counterparts (1.29a-f), though the quinolinyl-containing compounds (1.27a-f) displayed 
the greatest potency (Table 1.2). The authors noted that borazaronaphthalenes have a 
polarized B–N bond and a protic NH moiety, which can increase aqueous solubility 
relative to the naphthalene containing compounds. Direct comparison of the cLogP and 
IC50 values showed correlation between lower lipophilicity and higher inhibitory potency 
(Table 1.2). Trends between lipophilicty and metabolic clearance could not be identified. 
Co-crystallization of the compounds in the enzyme pocket could not be achieved, and 
thus the cause of the increased inhibition activity could not be concretely determined. 
                                                 
44 Grassberger, M. A.; Turnowsky, F.; Hildebrandt, J. Preparation and Antibacterial Activities of New 
1,2,3-Diazaborine Derivatives and Analogues. J. Med. Chem. 1984, 27, 947–953. 
45 Vlasceanu, A.; Jessing, M.; Kilburn, J. P. BN/CC Isosterism in Borazaronaphthalenes towards 







Another study from 2015 compared the pharmacokinetic profiles of two 
benzazaborinine analogues of propranolol with the carbonaceous version of the molecule 
(Table 1.3).46 It was found that compound 1.32 had a comparable pIC50 to propranolol 
(1.30) against the β2 adrenergic receptor and behaved similarly against β1 and 5HT1A 
receptors. Interestingly, experimental log D for both 1.31 and 1.32 were higher than 1.30, 
indicating that the BN heterocycles are more lipophilic. Both BN containing compounds 
showed greater metabolic stability than propranolol in human liver microsomes, though 
all three had high clearance rates in rat and mouse liver microsomes. Cytotoxicity tests, 
                                                 
46 Rombouts, F. J. R.; Tovar, F.; Austin, N.; Tresadern, G.; Trabanco A. A. Benzazaborinines as Novel 




however, showed that 1.31 and 1.32 had higher cytotoxicity than propranolol, which the 
authors posit might be due to the reduced aromaticity of the ring system. This decreased 
stability might lead to the formation of toxic metabolites at a higher rate than the more 
stable propranolol. Ames II tests for all three compounds were negative. 
Recently, a BN containing analogue of tryptophan 
(Figure 1.8) was synthesized and incorporated into a 
superfolder green fluorescent protein (sfGFP).47 Boknevitz 
et al. were able to demonstrate successful incorporation of 
the BN-tryptophan into sfGFP by cellular machinery and 
that the BN-tryptophan was not toxic to the E. coli. cells in which they were tested. 
Additionally, incorporation of BN-tryptophan into the non-fluorescent ketosteroid 
isomerase (KSI) protein produced a bathochromic shift in absorbance and emission 
compared to the wild type protein. BN-tryptophan containing KSI had a fluorescence 
maximum of 372 nm while the wild type KSI maximum was 342 nm. This demonstrates 
that incorporation of a BN heterocycle can change fluorescent properties of proteins 
without altering their steric profile. 
The first experimental evidence of the interaction of monocyclic 1,2-azaborines 
with biological systems was provided in 2009.48 N-ethyl-1,2-azaborine (1.34) and the 
parent 1,2-dihydro-1,2-azaborine (1.18) were found to bind in a mutated non-polar cavity 
of T4 lysozyme. The pocket was formed by the mutation of Leu99→Ala, forming a 
hydrophobic binding cavity. Binding of benzene in this pocket has been found to stabilize 
                                                 
47 Boknevitz, K.; Italia, J. S.; Li, B. Chatterjee, A.; Liu, S.-Y. Synthesis and Characterization of an 
Unnatural Boron and Nitrogen-Containing Tryptophan Analogue, and Its Incorporation into Proteins. 
Chem. Sci. 2019, 10, 4994–4998. 
48 Liu, L.; Marwitz, A. J. V.; Matthews, B. W.; Liu, S.-Y. Boron Mimetics: 1,2-Dihydro-1,2-azaborines 
Bind inside a Nonpolar Cavity of T4 Lysozyme. Angew. Chem. Int. Ed. 2009, 48, 6817–6819. 
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the protein.49 Importantly, it was found that the 1,2-azaborines bound in the pocket in a 
very similar manner to their carbonaceous isosteres.  
Further modification of this pocket by way of Met102→Gln caused the 
previously hydrophobic pocket to become polar. When 1.18 and N-hydro-B-ethyl-1,2-
azaborine (1.35) bind within the pocket, hydrogen bonding between the N–H bond of 
azaborine and the oxygen of the glutamine residue was observed.50 The Gln102=O···H–
N hydrogen bond distance was observed via crystal structure to be 3.1 and 3.2 Å for 1.18 
and 1.35, respectively. Additionally, the net free energy of binding was measured to be –
0.94 kcal mol-1 for 1.18 and –0.64 kcal mol-1 for 1.35. Additional studies showed that the 
strength of this hydrogen bonding decreases in discrete increments as further steric bulk 
is added to the boron position of the azaborine.51 
 
In addition to binding in enzymatic pockets, 1.34 and 1.35 have been shown to 
have similar biological activity to its carbonaceous isostere. Ethylbenzene dehydrogenase 
(EbDH) is an enzyme with a molybdenum cofactor that catalyzes the hydroxylation of 
ethyl benzene to (S)-1-phenylethanol. Unlike ethylbenzene, which is a substrate of 
                                                 
49 Eriksson, A. E.; Baase, W. A.; Wozniak, J. A.; Matthews, B. W. A Cavity-Containing Mutant T4 
Lysozyme is Stabilized by Buried Benzene. Nature 1992, 355, 371–373. 
50 Lee, H.; Fischer, M.; Shoichet, B. K.; Liu, S.-Y. Hydrogen Bonding of 1,2-Azaborines in the Binding 
Cavity of T4 Lysozyme Mutants: Structures and Thermodynamics. J. Am. Chem. Soc. 2016, 138, 12021–
12024. 
51 Liu, Y.; Liu, S.-Y. Exploring the Strength of a Hydrogen Bond as a Function of Steric Environment 




EbDH, both 1.34 and 1.35 were found to act as inhibitors of the enzymatic process.52 In 
particular, 1.34 was found to be a very efficient inhibitor with an IC50 of 2.8 µM. The 
mechanism of dehydrogenation via EbDH proceeds through both radical and carbocation 
transition states. Calculated ΔΔG values of the radical and carbocation forming steps on 
both 1,2-azaborines revealed energy levels substantially higher than that of ethylbenzene 
(Table 1.4). While both 1,2-azaborines can enter the enzymatic pocket of EbDH, their 
electronic structures prevent them from proceeding as substrates, leading to novel 
biological activity. 
 
Finally, in 2017 a series of three azaborine containing isosteres of biologically-
active compounds were synthesized and evaluated in vivo (Figure 1.10).53 Compound 
1.41 was evaluated as a dopamine D3 receptor antagonist. The dopamine D3 receptor has 
been tied to cognitive function in both healthy individuals and those with neurological 
disorders such as schizophrenia, Parkinson’s disease, and Alzheimer’s disease.54 
Compound 1.39 was evaluated as a PPAR γ and PPAR δ antagonist. PPAR γ is known to 
regulate glucose metabolism and insulin sensitization. Activation of PPAR δ enhances 
                                                 
52 Knack, D. H.; Marshall, J. L.; Harlow, G. P.; Dudzik, A.; Szaleniec, M.; Liu, S.-Y.; Heider, J. BN/CC 
Isosteric Compounds as Enzyme Inhibitors: N- and B-Ethyl-1,2-azaborine Inhibit Ethylbenzene 
Hydroxylation as Nonconvertible Substrate Analogues. Angew. Chem. Int. Ed. 2013, 52, 2599–2601. 
53 Zhao, P.; Nettleton, D. O.; Karki, R. G.; Zécri, F. J.; Liu, S.-Y. Medicinal Chemistry Profiling of 
Monocyclic 1,2-Azaborines. ChemMedChem 2017, 12, 358–361. 
54 Nakajima, S.; Gerretsen, P.; Takeuchi, H.; Caravaggio, F.; Chow, T.; Le Foll, B.; Mulsant, B.; Pollock, 
B.; Graff-Guerrero, A. The Potential Role of Dopamine D3 Receptor Neurotransmission in Cognition. Eur. 
Neuropsychopharmacol. 2013, 23, 799–813. 
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fatty acid metabolism. PPAR activity has been tied to a number of conditions including 
obesity, inflammation, pain, cancer, Parkinson’s disease, and Alzheimer’s disease.55 
Compound 1.37 was evaluated as an inhibitor of CDK2, which is a kinase that has been 
identified as a useful target for treatment and prevention of cancer.56 
 
                                                 
55 Tyagi, S.; Gupta, P.; Saini, A. S.; Kaushal, C.; Sharma, S. The Peroxisome Proliferator-Activated 
Receptor: A Family of Nuclear Receptors Role in Various Diseases. J. Adv. Pharm. Technol. Res. 2011, 2, 
236–240. 
56 Peng, C.; Zeng, W.; Su, J.; Kuang, Y.; He, Y.; Zhao, S.; Zhang, J.; Ma, W.; Bode, A. M.; Dong, Z.; 
Chen, X. Cyclin-Dependent Kinase 2 (CDK2) is a Key Mediator for EGF-Induced Cell Transformation 
Mediated through the ELK4/c-Fos Signaling Pathway.  Oncogene 2016, 35, 1170–1179. 
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When evaluated relative to their all carbonaceous isosteres, the three BN 
compounds all showed comparable potency. Of particular note was compound 1.37, 
which had an IC50 of 87 nM. The carbonaceous molecule (1.36), on the other hand, had a 
significantly larger IC50 of 320 nM. Further investigation of the properties of 1.36 and 
1.37 showed that the half-life, mean residence time, maximum concentration, clearance 
rate, bioavailability, and area under the curve were all improved in the BN isostere 
(Table 1.5). The addition of the BN unit results in 1.36 having increased bioavailability 
relative to 1.37. This enhanced biological activity can in part be attributed to the 
hydrogen bonding interaction at the N–H of the azaborine. Binding models of 1.37 in the 
cavity of CDK2 indicated a likely hydrogen bond between the backbone carbonyl of 
Ile10 and the azaborine N–H. ADMET behavior of the molecules indicates increased 




1.2.2 Late Stage Functionalization of 1,2-Azaborines 
The study of 1,2-azaborines as pharmacophores in medicinal chemistry requires 
synthetic strategies for their incorporation into the molecular framework of complex 
drug-like molecules. To this end, one focus of recent azaborine research has been on late 
stage functionalization of 1,2-azaborines. Unlike benzene, each position on the azaborine 
ring is electronically distinct; there is significant electron density at the C3- and C5-
positions,57 which can be illustrated by electrostatic potential maps and explained via 
resonance structures. (Figure 1.11)58 This electronic distinction should theoretically 
allow for each position of the azaborine ring to be activated selectively. For the purpose 
of this chapter, only the carbon positions of 1,2-azaborine, i.e. positions C3-C6, will be 
discussed. 
 
The electron-rich C3-position of 1,2-azaborine will selectively undergo 
electrophilic aromatic substitution. This transformation was first reported by Ashe in 
                                                 
57 Marwitz, A. J. V.; Matus, M. H.; Zakharov, L. N.; Dixon, D. A. Liu, S.-Y. A Hybrid Organic/Inorganic 
Benzene. Angew. Chem. Int. Ed. 2009, 48, 973–977. 
Electrostatic Potential map at the 0.002 electron/a.u.3 density iso-contour level. Blue is positive potential, 
red is negative potential, and green represents near zero potential.  
58 Electrostatic Potential map at the 0.002 electron/a.u.3 density iso-contour level. Blue is positive potential, 
red is negative potential, and green represents near zero potential.  
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2007.59 A number of functional groups were installed via this transformation with 
complete regioselectivity, including bromine, iodine, nitrile, and deuterium. While Ashe 
was able to functionalize the 3-position in N-Ethyl-B-phenyl-1,2-azaborine, electrophilic 
substitution in the presence of a B–Cl bond has also been demonstrated, notably by the 
Liu group in 200960 and 201561. Development of late stage functionalization in the 
presence of a B–Cl bond is significant as this bond is labile and can be readily 
functionalized to add further chemical diversity. In the 2015 report, the Liu group was 
also able to demonstrate functionalization of the C3-Br in the presence of a B–Cl bond 
via a Negishi cross coupling, a method tolerant of alkyl, alkenyl, and aryl zinc halides at 
room temperature (Scheme 1.2). An additional study in 2019 further expanded the 
Negishi reaction to 1,2-azaborines with a B–H bond.62 The presence of the more stable 
B–H bond allowed for more electron rich arenes to be used as substrates, which 
otherwise would generate a mixture of B–O species in the presence of a B–Cl bond. 
                                                 
59 Pan, J.; Kampf, J. W.; Ashe, A. J –681. 
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BioSyst. 2009, 5, 1303–1305. 
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62 Brown, A. N.; Li, B.; Liu, S.-Y. Expanding the Functional Group Tolerance of Cross-Coupling in 1,2-
Dihydro-1,2-azaborines: Instillation of Alkyl, Alkenyl, Aryl, and Heteroaryl Substituents While 




C–H borylation is currently the only published method for late-stage 
functionalization at the C6-position of 1,2-azaborines.63 Borylation takes place 
selectively at the 6-position through iridium catalysis. Iridium catalyzed C–H borylation 
of arenes has been shown to favor activation of the most acidic C–H bonds.64 
Calculations have shown that that the C6-position of 1,2-azaborine has the lowest pKa,63 
                                                 
63 Baggett, A. W.; Vasiliu, M.; Li, B.; Dixon, D. A.; Liu, S.-Y. Late-Stage Functionalization of 1,2-
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Singleton, D. A.; Smith III, M. R. Electronic Effects in Iridium C–H Borylations: Insights from 
Unencumbered Substrates and Variation of Boryl Ligand Substituents. Chem. Comm. 2010, 7724–7726. 
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in agreement with its electron deficient nature.  The reaction was carried out on 1,2-
azaborines with hydride, alkoxy, alkyl, or aryl groups at the B-position and a proton at 
the N-position. The borylated azaborines can then be submitted to Suzuki cross coupling 
conditions with an aryl- and heteroaryl-bromide cross coupling partner, further 
introducing diversity to the azaborine core (Scheme 1.3). 
 
In the presence of a bulky TBS group at the N-position, iridium catalyzed 
borylation will install Bpin at both the C4- and C5-position in a ratio of 1:1.3 (Scheme 
1.4).65 The electronic differences at the C4- and C5- position allow for resolution and 
isolation of these two products, 1.49 and 1.50. N-methylmorpholine-N-oxide selectively 
oxidizes 1.50, allowing 1.49 to be isolated. An iridium catalyzed deborylation is selective 
for 1.49, allowing 1.50 to be isolated. While this method is effective, it limits the 
maximum theoretical yield of borylation of either position on azaborine to 50%. 
Additionally, both resolutions were only demonstrated to be effective on B-mesityl-1,2-
azaborines, which makes further modification of the azaborine core at the B-position 
challenging.  
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 Electrophilic aromatic substitution has been demonstrated to be selective for the 
C5-position of 1,2-azaborines under select conditions (Scheme 1.5). Ashe demonstrated 
that a Mannich reaction will take place selectively at the C5-position of 1.42 to afford 
product 1.52 in 60 % yield.59 In a study of the acylation of 1,2-azaborines, Fang found 
that acylation of 1.53 could proceed selectively at the C5-poisition to yield products 
1.54a-h. This selectivity is likely in part due to the steric bulk of the mesityl group.66 In a 
separate report, Fang reported conditions for selectively nitrating the C5-position of the 
same substrate to yield the C5-nitrated product 1.55.67 
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While these methods exist for functionalizing the C5-position, there is no known 
protocol for selectively installing a functional group handle with broad synthetic utility. 
Additionally, all selective transformations at the C5-position have been demonstrated 
with a bulky mesityl or other aryl group at the B-position, making further 
functionalization of the molecule at that position difficult. No methods currently exist for 
directly installing functionality exclusively at the C4-position. In the following section, 
efforts to increase the scope and utility of the late stage functionalization of 1,2-
azaborines will be detailed. Specifically, the installation of chemical handles on the core 
of 1,2-azaborines with the explicit goal of synthesizing biologically active azaborine-
containing compounds will be detailed.  
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1.3 Towards the Synthesis of a Tetra-Orthogonally Reactive 1,2-Azaborine 
1.3.1 Identifying 3,5-Dibromo-N-TBS-B-Cl-1,2-azaborine as a Synthetic Target 
To date, the only 1,2-azaborine containing druglike compounds that have been 
synthesized and published have had substitution exclusively at the 2-position. This is due 
in part to synthetic limitations of functionalizing 1,2-azaborines at other positions. Many 
biphenyl druglike molecules, which are prime candidates for investigating BN/CC 
isosterism, have more complex substitution patterns that are currently inaccessible on 
azaborines using known functionalization methods. In order to broaden the scope of 
targets in which we can incorporate azaborine, it is imperative to develop site selective 
and orthogonally reactive methods of substituting around the core of the 1,2-azaborine. 
Our vision is to develop a tetra-orthogonally reactive azaborine with 
electronically distinct handles at the C3- and C5-positions. Such a molecule would enable 
us to access a wider array of biaryl structures with substituents ortho and para to the 
group at the boron position.  This would allow for the development of more targets to 
explore the medicinal chemistry profile of 1,2-azaborine. Because of the preference of the 
C3-position for electrophilic aromatic substitution, it was hypothesized that the C5- and 
C3-positions of a 3,5-dibromo-N-TBS-B-Cl-1,2-azaborine would be electronically 
distinct enough to selectively undergo further transformations selectively. Of utmost 
importance was maintaining the TBS- and Cl-functionality at the N- and B-positions, 
respectively, so that these positions could easily undergo further transformations. We 
have previously demonstrated that the TBS and Cl groups can easily be removed from the 
1,2-azaborine and replaced with an array of other functionalities.56,61,68,69,70 
                                                 
68 Rudebusch, G. E.; Zakharov, L. N.; Liu, S.-Y. Rhodium-Catalyzed Boron Arylation of 1,2-Azaborines. 
Angew. Chem. Int. Ed. 2013, 52, 9316–9319. 
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1.3.2 Synthesis and Evaluation of 3,5-Dibromo-N-TBS-B-Cl-1,2-azaborine 
N-TBS-B-Cl-1,2-azaborine (1.45), which is commercially available,71 was 
selectively brominated at the C3-position through conditions that have been previously 
described.58 A successive bromination was accomplished by resubjecting purified 1.46 to 
bromination conditions, affording 1.56 in 60% yield. Because C5 was the only 
nucleophilic position available for bromination on the azaborine, the reaction could be 
run at room temperature. Additionally, a slight excess of bromine was required for full 
bromination to take place. Attempts to synthesize 1.56 directly from 1.46 using multiple 
equivalents of bromine were unsuccessful.  
A Suzuki reaction was attempted to test whether the C3–Br bond and the C5–Br 
bond of 1.57 were sufficiently electronically distinguishable to be selectively activated. 
As the labile B–Cl bond was likely to lead to undesired reactions, substitution at the B-
position was performed to convert 1.56 to 1.57 via a Grignard reaction. We envision our 
tetra-orthogonally reactive scaffold would be used as a starting point to synthesize a 
number of different biologically-relevant azaborine-containing molecules, and methods 
for addition of a wide range of groups at the B-position will be discussed in the following 
chapter.  
For the purpose of exploring fundamental reactivity, a B–phenyl-1,2-azaborine 
was chosen as a model compound. The transformation was achieved by reacting 1.56 
with phenyl magnesium bromide in tetrahydrofuran to afford 1.57 in good yield. Our 
                                                                                                                                                 
69 Marwitz, A. J. V.; Abbey, E. R.; Jenkins, J. T.; Zakharov, L. N.; Liu, S.-Y. Diversity through Isosterism: 
The Case of Boron-Substituted 1,2-Dihydro-1,2-azaborines. Org. Lett. 2007, 9, 4905–1908. 
70 Lamm, A. N.; Garner, E. B.; Dixon, D. A.; Liu, S.-Y. Nucleophilic Aromatic Substitution Reactions of 
1,2-Dihydro-1,2-Azaborine. Angew. Chem. Int. Ed. 2011, 50, 8157-8160. 
71 Compound 1.45 is now commercially available from www.strem.com, catalog number 05-0150. 
Accessed on 27 Sept 2019. 
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model compound (1.57) was subjected to Suzuki conditions, but we were unable to 
identify any positional selectivity amongst the mixture of products. It was determined 
that the C3-Br and C5-Br were too electronically similar to realize our goal of a tetra-
orthogonally reactive azaborine with this substitution pattern. 
 
1.3.3 Synthesis of 3-Bromo-5-iodo-N-TBS-B-OH-1,2-azaborine 
Our limited tests indicated that 1.57 was not a suitable substrate to achieve 
selective activation of either the C5- or C3-position. To allow for adequate distinction 
between chemical handles we believed that different moieties would need to be installed 
at the C3- and C5-positions. Because an (Csp2)–I bond is significantly weaker than an 
(Csp2)–Br bond,30 the installation of iodine at the C5-position while maintaining a C3–Br 
bond should provide sufficient electronic distinction between the two sites.  
A number of conditions were screened to achieve iodination of 1.46 at the C5-
position (Table 1.6). Unlike in the bromination reaction, molecular iodine was not 
reactive enough to achieve the desired addition. Several Lewis acids were screened in an 
effort to increase the electrophilicity of iodine, and only gold (III) trichloride was 
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effective. However, yields above 17% could not be achieved with gold (III) trichloride, 
and stoichiometric amounts of Lewis acid led to decomposition of the azaborine. As 
Lewis acids were unable to promote iodination with molecular iodine, we screened two 
reagents bearing more electrophilic iodine moieties. While iodine monochloride led to 
decomposition of 1,2-azaborine, 1H NMR indicated that N-iodosuccinimide did undergo 
electrophilic aromatic substitution at the C5-position, warranting further investigation. 
 
Use of N-iodosuccinimide presented a unique challenge, however. During the 
course of the reaction a negatively charged, nucleophilic nitrogen species is produced 
after abstraction of iodine by 1.46. This nucleophilic species can then attack the 
azaborine, forming a side product (1.59) in which the succinimide group added to the 
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azaborine at the electrophilic B-position, breaking the labile B–Cl bond. As a result, both 
1.58 and 1.59 were observed in the crude reaction mixture by 1H NMR analysis. This 
challenge notwithstanding, optimization of the reaction conditions was pursued. The 
reaction proceeded to its highest conversion (61%, 1:1.3 1.58 to 1.59) with three 
equivalents of N-iodosuccinimide. The remaining mass balance was unreacted 1.46. Four 
equivalents of N-iodosuccinimide led to decreased yield and decomposition of starting 
material (Table 1.7).  
 
It was found that by passing the crude reaction mixture through a PTFE filter in 
pentane, the azaborine species could largely be separated from the other species in the 
reaction. By allowing this filtrate to stir in the presence of boron trichloride, a 
comproportionation reaction takes place, regenerating 1.58 as the only azaborine species 
in solution (as determined by 1H NMR). However, 1.58 proved to be unstable both 
towards silica gel chromatography and at the elevated temperature that is needed for 




While decomposition at high temperatures needed for the distillation of bromine 
and iodine substituted 1,2-azaborine would be difficult to avoid, an appropriate group at 
the B-position could help protect the azaborine from decomposition during 
chromatography. We have previously demonstrated that unlike B–Cl azaborine, B–OR 
species are stable on silica.72 Compound 1.46 was thus treated with methanol in the 
presence of triethyl amine to yield 1.60, which was purified via silica gel 
chromatography. Compound 1.60 was stirred in the presence of N-iodosuccinimide to 
generate intermediate 1.61. Presence of a B–OMe bond instead of a B–Cl bond had 
several effects on this reaction. A smaller amount of N-iodosuccinimide was necessary to 
achieve full conversion of starting material. Additionally, the B–OMe protects against 
nucleophilic attach by succinimide and no B–N species were observed.  
                                                 
72 (a) Abbey, E. R.; Lam, A. N.; Baggett, A. W.; Zakharov, L. N.; Liu, S.-Y. Protecting Group-Free 
Synthesis of 1,2-Azaborines: A Simple Approach to the Construction of BN-Benzenoids. J. Am. Chem. 
Soc. 2013, 135, 12908–12913. (b) Baggett, A. W.; Liu, S.-Y. A Boron Protecting Group Strategy for 1,2-




Species 1.61 showed some decomposition to an unknown azaborine species when 
purified via silica gel chromatography. However, chromatography on alumina gel yielded 
product with both C3–Br and C5–I bonds intact. Curiously, after being passed through an 
alumina gel column, the B–OMe bond was replaced with a B–OH bond (1.62). To ensure 
full conversion to 1.62, the reaction mixture was washed with pentane and passed 
through a PTFE filter to isolate 1.61. Isolated 1.61 was stirred in the presence of water to 
generate 1.62 before purification via alumina gel chromatography. 1.62 was found to be 
stable to silica and under air at ambient temperatures. Several attempts were made to 
convert the B–OH species to a B–OR species without success.73  
                                                 




It has been demonstrated that 1,2-azaborines can act as bioisosteres of 
benzene.46,47 The unique electronic properties of 1,2-azaborines can be leveraged to 
change not only the ADMET properties of target molecules but also influence their 
mechanisms of binding within enzymatic pockets. Despite the proven value of 1,2-
azaborines in drug development, improved synthetic accessibility is necessary for further 
studies, particularly with regard to addition of functionality at the carbon positions of the 
azaborine ring. 
Towards this end, we have described the synthesis of N-TBS-B-OH-3-bromo-5-
iodo-1,2-azaborine, which may act as a tetra-orthogonally reactive azaborine core. By 
installing different halogens at the C3- and C5-positions, it could be possible to 
selectively and sequentially functionalize these positions through any number of 
transformations that proceed from halogenated starting materials. N-TBS deprotection 
and further functionalization at the N-position has been well documented in 1,2-
azaborines. While B–OH species have yet to be studied, other B–OR species have been 
shown to be competent precursors to a number of different B–R substituted azaborine 




1.5.1 General Considerations 
Unless otherwise noted, all oxygen- and moisture-sensitive manipulations were 
carried out in flame-or oven-dried glassware under an atmosphere of nitrogen using either 
standard Schlenk technique or a nitrogen-filled glove box. Oxygen-sensitive 
manipulations carried out in the presence of degassed water were done so in a nitrogen 
filled, wet glove box. THF, CH2Cl2, and pentane were dried using a Brady® solvent 
purification system, which consisted of columnar molecular sieves under argon 
atmosphere. All column chromatography was performed by hand in a nitrogen-filled 
glove box. Silica gel (230-400 mesh) and alumina gel were dried for 18 hours at 240 ºC 
under high vacuum. All reagents were purchased from commercial vendors (Acros 
Organics®, Millipore Sigma®, TCI®) and used as received unless otherwise noted.  
All NMR spectra were recorded on a Varian VNMRS 500 MHz or INOVA 500 
MHz spectrometer at ambient temperature in the Michael Gerson Magnetic Resonance 
and Instrumentation Laboratory at Boston College. 11B NMR spectra were externally 
referenced to BF3·Et2O (δ 0.0 ppm). 1H NMR spectra were internally referenced to 
chloroform-d3 (δ 7.26 ppm). Infrared spectroscopy was performed on a Bruker ALPHA-
Platinum FT-IR Spectrometer with an ATR-sampling module. High-resolution mass 
spectrometry analysis was performed by Marek Domin on a JEOL AccuTOF instrument 
equipped with a DART ion source in positive ion mode at the Boston College Center for 
Mass Spectrometry.   
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1.5.2 Synthesis of 1,2-Azaborines 
1.45 (1.50 g, 6.59 mmol) was dissolved in 10.0 mL of dichloromethane in a 
100 mL roundbottom flask and allowed to stir under nitrogen. The reaction 
mixture was cooled to –40 °C in a dry ice/acetone bath. Molecular bromine 
(1.11 g, 6.92 mmol) was dissolved in 1.5 mL of dichloromethane and added dropwise to 
the flask. The reaction mixture changed from clear and colorless to a shallow orange 
color after addition of bromine. The reaction was allowed to warm to 0 °C over the 
course of 1 hour. At the conclusion of the reaction, the reaction mixture was concentrated 
in vacuo. The crude reaction mixture was purified via vacuum distillation (140 °C, 200 
mtorr). 1.46 was collected at 90 °C as a light yellow oil (1.62 g, 80.3% yield). 
Spectra of isolated compound matched previously published records.61  
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1.46 (2.90 g, 9.46 mmol) was dissolved in 3.0 mL of dichloromethane 
in a 50 mL roundbottom flask and allowed to stir under nitrogen at      
24 °C. Molecular bromine (2.42 g, 15.14 mmol) was dissolved in 3.0 
mL of dichloromethane and added dropwise to the flask, after which the reaction mixture 
changed from clear and colorless to a rich red color. The reaction mixture was allowed to 
stir for 2 hours. At the conclusion of the reaction, the reaction mixture was concentrated 
in vacuo. The crude reaction mixture as purified via vacuum distillation (210 °C, 300 
mtorr). 1.56 was collected at 95 °C as a golden oil (1.12 g, 30.8% yield) 
1H NMR (500 MHz, CDCl3) δ 7.96 (s, 1H), δ 7.36 (s, 1H), δ 0.96 (s, 9H), δ 0.57 (s, 6H); 
13C NMR (125 MHz, CDCl3) δ 148.83, 137.67, 104.12, 28.59, 19.30, -1.61 (one C 
bonded to B was not observed); 11B NMR (160 MHz, CDCl3) δ 33.784; FTIR (thin film) 
ῦ = 2953, 2929, 2884, 2858, 1603, 1440, 1348, 1317, 1260, 1103, 999, 843, 810, 759, 




1.56 (250 mg, 0.649 mmol) was dissolved in 5 mL of tetrahydrofuran 
in a 25 mL roundbottom flask and allowed to stir at 24 °C. A 3M 
solution of phenyl magnesium bromide in diethyl ether (0.259 mL, 
0.778 mmol) was added dropwise to the reaction mixture. The reaction was allowed to 
stir for 5 hours, after which the reaction mixture turned from a light yellow color to a 
clear, vibrant orange. At the conclusion of the reaction, 0.1 mL of methanol was added to 
the reaction mixture, which immediately produced a bright red color. The reaction 
mixture was concentrated in vacuo, and purified via silica gel chromatography (15-50% 
dichloromethane in pentane). 1.57 was collected as an off-white solid (230 mg, 83.0% 
yield). 
1H NMR (500 MHz, CDCl3) δ 8.04 (s, 1H), δ 7.53 (s, 1H), δ 7.35-7.33 (m, 3H), δ 7.31-
7.29 (m, 2H) δ 0.90 (s, 9H), δ 0.02 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 147.28, 
137.50, 132.11, 127.57, 126.97, 104.89, 28.68, 18.85, -2.30 (two Cs bonded to B were 
not observed); 11B NMR (160 MHz, CDCl3) δ 37.373; FTIR (thin film) ῦ = 2954, 2930, 
2885, 2858, 1607, 1440, 1363, 1348, 1260, 1128, 998, 842, 811, 732, 681; HRMS 
(DART+) calculated for C16H22BNBr2Si (M+): 424.99758, observed: 424.99827.  
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1.46 (4.71 g, 15.37 mmol) was dissolved in 20 mL of dichloromethane in a 
100 mL roundbottom flask and allowed to stir at 24 °C. A solution 
of methanol (0.654 mL, 16.13 mmol), distilled off of calcium 
hydride, and triethylamine (3.21 mL, 23.05 mmol), distilled off of calcium hydride, in 10 
mL of dichloromethane was added dropwise to the vial and allowed to stir for 1.5 hours. 
The reaction mixture turned from a clear yellow color to an opaque off-white color with a 
significant presence of a precipitate. At the conclusion of the reaction, the reaction 
mixture was diluted with pentane (50 mL), causing additional precipitate to crash out of 
solution. The crude reaction mixture was reduced in vacuo and purified via silica gel 
chromatography (20% dichloromethane in pentane). 1.60 was collected as a clear, lightly 
yellow oil (3.88 g, 83.6% yield). 
1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 6.5, 1H), δ 7.00 (d, J = 6.5, 1H), δ 5.77 (t, J = 
7, 3H), δ 4.03 (s, 3H) δ 0.91 (s, 9H), δ 0.37 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 
149.00, 138.00, 106.80, 53.88, 26.80, 18.88, -2.91 (one C bonded to B was not observed); 
11B NMR (160 MHz, CDCl3) δ 27.908; FTIR (thin film) ῦ = 2954, 2929, 2884, 2858, 
1603, 1470, 1356, 1286, 1252, 1128, 998, 906, 841, 823, 732, 681; HRMS (DART+) 
calculated for C11H21BNOBrSi (M+): 302.07416, observed: 302.07412.  
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1.60 (1.50 g, 4.97 mmol) was dissolved in 20 mL of dichloromethane in 
a 100 mL vial and was allowed to stir at 24 °C. N-iodosuccinimide (1.51 
g, 6.70 mmol), recrystallized from a dioxane/pentane mixture, was added 
to the vial as a solid. The reaction was allowed to stir for 24 hours, after which the 
reaction mixture changed in color from translucent red to a deep, opaque black. At the 
conclusion of the reaction, solvent was removed from the crude in vacuo. Concentrated 
crude was dissolved in 15% dichloromethane in pentane (20 mL) and purified via 
alumina gel chromatography (15% dichloromethane in pentane) to yield a mixture of 
1.61 and 1.62 as a clear, orange liquid. This mixture was dissolved in 20 mL of 
dichloromethane and allowed to stir at 24 °C. Degassed water (0.270 mL, 14.91 mmol) 
was added to flask, which was allowed to stir under nitrogen atmosphere for 1 hour. The 
reaction mixture was allowed to stir over activated molecular sieves for 2 hours, after 
which it was transferred via cannula to a dry 50 mL roundbottom flask and concentrated 
in vacuo. Crude reaction mixture was purified via alumina gel chromatography (15% 
dichloromethane in pentane). 1.62 was collected as an orange solid (1.17 g, 57.0% yield). 
1H NMR (500 MHz, CDCl3) δ 7.80 (s, 1H), δ 7.17 (s, 1H), δ 4.62 (s, 1H), δ 0.93 (s, 9H), 
δ 0.43 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 151.48, 142.17, 26.33, 18.75, -3.67 (one C 
bonded to B and one C bonded to I were not observed); 11B NMR (160 MHz, CDCl3) δ 
28.689; FTIR (thin film) ῦ = 3612, 2952, 2928, 2884, 2857, 1581, 1470, 1387, 1343, 
1258, 1007, 842, 811, 680; HRMS (DART+) calculated for C10H18BNOBrISi (M+): 




1.5.3 Attempts to Regenerate N-TBS-B-OMe-3-bromo-5-iodo-1,2-azaborine 
 Several attempts were made to regenerate 1.61 from 1.62 by nucleophilic attack 
of methanol at the B-position (Table 1.8). Drying agents seemed unable to push the 
reaction to the product. Large excesses of methanol was equally ineffective and only 
served to cause decomposition of the azaborine core. 
 
 An attempt was also made to deprotonate the protic hydrogen bound to oxygen 
and attack a methyl electrophile (Scheme 1.9). While deprotonation was observed via 11B 





































Development of a Functional Group Tolerant Grignard-Type Reaction for Addition 
to the B-Position of 1,2-Azaborines 
2.1  Introduction: The Turbo Grignard Reagent  
2.1.1 Limitations of the Traditional Grignard Reaction 
What is now known as the Grignard reaction was first reported over 100 years ago 
by Victor Grignard. In the last year of the nineteenth century, Grignard reported the 
formation of secondary and tertiary alcohols by reacting alkyl magnesium halides with 
aldehydes and ketones (Scheme 2.1).1 The importance of Grignard’s reaction was 
quickly recognized, as he was awarded the Nobel Prize in Chemistry in 1912.2 Grignard’s 
reagent has since found a wide array of applications in organic and organometallic 
chemistry,3 and remains one of the most widely utilized organometallic reagents.2 
 
                                                 
1 (a) Grignard, V. Sur quelques nouvelles combinaisons organométaliques du magnesium et leur 
application à des syntheses d’alcools et d’hydrocabures. Compt. Rend. 1900, 130, 1322–1325. (b) 
Rheinboldt, H. Fifty Years of the Grignard Reaction. J. Chem. Ed. 1950, 27, 476–488. 
2 Seyferth, D. The Grignad Reagents. Organometallics 2009, 28, 1598–1605. 
3 For selected reviews on uses of Grignard reagents, see: (a) Mako, T. L.; Byers, J. A. Recent Advances in 
Iron-Catalyzed Cross Coupling Reactions and Their Mechanistic Underpinning. Inorg. Chem. Front. 2016, 
3, 766–790.  (b) Knappke, C. E. I.; von Wangelin, A. J. 35 Years of Palladium-Catalysed Cross-Coupling 
with Grignard Reagents: How Far Have We Come? Chem. Soc. Rev. 2011, 40, 4948–4962. (c) 
Harutyunyan, S. R.; den Hartog, T.; Geurts, K. Minnaard, A. J.; Feringa, B. L. Catalytic Asymmetric 
Conjugate Addition and Allylic Alkylation with Grignard Reagents. Chem. Rev. 2008, 108, 2824–2852. (d) 
Cherney, A. H.; Kadunce, N. T.; Reisman, S. E. Enantioselective and Enantiospecific Transition-Metal-
Catalyzed Cross-Coupling Reactins of Organometallic Reagents to Construct C–C Bonds. Chem. Rev. 
2015, 115, 9587–9652. (e) Sun, C.-L.; Shi, Z.-J. Transition-Metal-Free Coupling Reactions. Chem. Rev. 
2014, 114, 9219–9280. (f) Jana, R.; Pathak, T. P.; Sigman, M. S. Advances in Transition Metal (Pd,Ni,Fe)-




 The Grignard reaction allows for the formation of carbon–carbon bonds between 
the nucleophilic Grignard reagent and an electrophilic species. The Grignard reagent is 
formed when magnesium undergoes an oxidative insertion at a carbon–halogen bond. 
This resulting carbon–magnesium bond has partial positive charge on the magnesium and 
partial negative charge on the carbon, creating a nucleophilic carbon species. The 
strength of this nucleophilic species is dependent on the electronegativity difference 
between the carbon and the metal; increasingly polarized bonds result in more 
nucleophilic species (Figure 2.1).4 
 
 For less electropositive metals, it is currently impossible to prepare 
organometallic compounds by direct reaction of the organic halide with the zero valent 
metal species.5 On the other hand, highly electropositive metals such as lithium form 
strong nucleophiles that are reactive towards most functional groups. A narrow selection 
of functional group tolerant organolithium compounds can be generated, but only at 
temperatures between –100 and –78 °C, limiting synthetic utility.6 Formation of classical 
                                                 
4 Boudieer, A.; Bromm, L. O.; Lotz, M.; Knochel, P. New Applications of Polyfunctional Organometallic 
Compounds in Organic Synthesis. Angew. Chem. Int. Ed. 2000, 39, 4414–4435. 
5 Rieke, R. D. Preparation of Organometallic Compounds from Highly Reactive Metal Powders. Science 
1986, 246, 1260–1264. 
6 (a) Parham, W. E.; Jones, L. D. Elaboration of Bromoarylnitriles. J. Org. Chem. 1976, 41, 1187–1191. (b) 




Grignard reagents will only tolerate a limited number of functional groups, and react 
readily with ketones, aldehydes, esters, nitriles, and epoxides.5 An effective strategy for 
developing more functional group tolerant Grignard reactions is to increase the reactivity 
of the metal towards organic substrates. This increased reactivity allows for more facile 
insertion into the C–X bond, which allows the reaction to occur at lower temperatures, 
safeguarding sensitive functional groups.  
 
 Rieke was able to generate highly reactive magnesium by reducing MgCl2 or 
MgBr2 in the presence of Li with naphthalene as an electron carrier. This activated 
magnesium could undergo oxidative insertion with bromobenzene at temperatures as low 
as -78 °C, and even could undergo oxidative insertion with fluorobenzene, which is the 
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most stable of the carbon–halogen bonds.5,7 While this more reactive magnesium was an 
improvement, it still required temperatures of –78 °C and could only tolerate a narrow 
selection of functional groups.8 For example, only bulky esters, nitriles, and chlorine 
groups were tolerated, and the reactions occurred at such low temperatures that only 
aldehydes could act as competent electrophiles (Table 2.1). 
 Another method for increasing functional group tolerance of Grignard reactions is 
using alkyl–magnesium bromide species to form Grignard reagents (Scheme 2.2) via 
magnesium-bromine exchange. Use of alkyl–magnesium reagents is particularly useful 
for forming C(sp2)–Mg bonds, as the thermodynamic stability of the product vis-à-vis the 
alkyl–magnesium reagent is the driving force behind generation of the Grignard reagent.  
 
This strategy was first employed by Prévost in 1931 by generating an allylic 
Grignard reagent using ethyl magnesium bromide as a magnesium source.9,10 Additional 
work was performed in the 1970s on heavily fluorinated bromobenzenes,11 and further 
studies determined that the rate of magnesium-bromine exchange was increased with 
                                                 
7 (a) Rieke, R. D.; Hudnall, P. M. Activated Metals. I. Preparation of Highly Rective Magnesium Metal. J. 
Am. Chem. Soc. 1972, 94, 7178–7179. (b) Rieke, R. D.; Li, P. T.-J.; Burns, T. P.; Uhm, S. T. Preparation of 
Highly Reactive Metal Powders. New Procedure for the Preparation of Highly Reactive Zinc and 
Magnesium Metal Powders. J. Org. Chem. 1981, 46, 4323–4324. (c) Burns, T. P.; Rieke, R. D. Highly 
Reactive Magnesium and Its Application to Organic Syntheses. J. Org. Chem. 1987, 52, 3674–3680. 
8 Lee, J.-S.; Velarde-Ortiz, R.; Guijarro, A.; Wurst, J. R.; Rieke, R. D. Low-Temperature Formation of 
Functionalized Grignard Reagents from Direct Oxidative Addition of Active Magnesium to Aryl Bromides.  
J. Org.Chem. 2000, 65, 5428–5430. 
9 Prévost, C. The Action of Action of α-Ethyleneic Bromides on Organomagnesium Bromides-Collected 
Results. Bull. Soc. Chim. Fr. 1931, 49, 1372. 
10 Knochel, P.; Dohle, W.; Gommermann, N.; Kneisel, F. F.; Kopp, F.; Korn, T.; Sapountzis, I.; Vu, V. A. 
Highly Functionalized Organomagnesium Reagents Prepared through Halogen–Metal Exchange. 
11 Tamborski, C.; Moore, G. J. Synthesis of Polyfluoroaromatic Magnesium Compounds through the 
Exchange Reaction. J. Organometal. Chem. 1971, 26, 153–156. 
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additional electron withdrawing groups present.12 Even bromobenzenes with electron 
donating methoxy groups were found to undergo magnesium-halogen exchange with 
iPrMgCl, though this was likely due to the directing effect of oxygen adjacent to the 
labile C–Br bond.13 While magnesium-bromine exchange using iPrMgBr or related 
alkyl–magnesium species faced difficulties in activating C–Br bonds without additional 
electron withdrawing groups present, it was found to be effective in activating C–I bonds 
in the presence of sensitive functional groups or non-directing electron donating groups 
(Table 2.2).14 The weaker C–I bond allowed for a more facile magnesium-iodine 
exchange that could be carried out at reduced temperatures, leading to higher functional 
group tolerance. 
 
                                                 
12 Abarbri, M.; Dehmel, F.; Knochel, P. Bromine-Magnesium-exchange as a General Tool for the 
Preparation of Polyfunctionl Aryl and Heteroaryl Magnesium-Reagents. Tetrahedron Lett. 1999, 40, 7449–
7453. 
13 Nishiyama, H.; Isaka, K.; Itoh, K.; Ohno, K.; Nagase, H.; Matsumoto, K.; Yoshiwara, H. Metal–Halogen 
Exchange between Polybromoanisoles and Aliphatic Grignard Reagents: A Synthesis of 
Cyclopenta[b]benzofurans. J. Org. Chem. 1992, 57, 407–410. 
14 (a) Rottländer, M.; et al. New Polyfuctional Magnesium Reagents for Organic Synthesis. Chem. Eur. J. 
2000, 6, 767–770. (b) Boymond, L.; Rottländer, M.; Cahiez, G.; Knochel, P. Perparation of Highly 
Functionalized Reagents by an Iondine–Magnesium Eschange Reaction and its Application in Solid-Phase 
Synthesis. Angew. Chem. Int. Ed. 1998, 37, 1701–1703. 
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2.1.2 Use of iPrMgCl·LiCl to Achieve Broad Functional Group Tolerance 
Despite advances of alkyl–magnesium reagents, methods for forming functional 
group tolerant Grignard reagents still excluded many sensitive moieties and there is still 
difficulty in activating C–Br bonds, especially in the presence of sensitive chemical 
groups.15 In 2004, Knochel discovered that by adding LiCl salt to a solution of iPrMgCl, 
more challenging magnesium-bromine exchanges could be achieved (Table 2.3). Thus, 
the turbo Grignard reagent, iPrMgCl·LiCl, was discovered as a powerful tool for creating 
polyfunctionalized Grignard reagents.16 
 
Knochel’s method allowed him to access a wealth of new Grignard reagents that 
were previously inaccessible through simpler alkyl–magnesium reagents (Table 2.4). Use 
of iPrMgCl·LiCl resulted in higher yields than traditional iPrMgCl or iPr2Mg reagents at 
room temperature, suggesting more facile insertion between the C–Br bond.16 The power 
of the turbo Grignard reaction is due to the presence of the Lewis acidic lithium. The 
                                                 
15 Ziegler, D. S.; Wei, B.; Knochel, P. Improving the Halogen–Magnesium Exchange by Using New 
Turbo0Grignard Reagents. Chem. Eur. J. 2018, 25, 2695–2703. 
16 Krasovskiy, A.; Knochel P. A LiCl-Mediated Br/Mg Exchange Reaction for the Prearation of 
Functionalized Aryl- and Heteroarylmagnesium Compounds from Organic Bromides. Angew. Chem. Int. 
Ed. 2004, 43, 3333–3336. 
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lithium gives more magnesiate character to the Grignard reagent, resulting in species with 
the distinct charge distribution of [Li]+[RMgCl2]-. In this way, lithium “activates” 
iPrMgCl and increases the nucleophilic character of the isopropyl group, leading to 
quicker exchange with carbon–halogen bonds. Additionally, the LiCl salt likely breaks up 
polymeric aggregates of iPrMgCl in solution, improving solubility.17,18 
 
 In addition to the nitrile and bulky esters tolerated in Knochel’s original work, a 
number of other sensitive functional groups have been shown to survive magnesium–
                                                 
17Blasberg, F.; Bolte, M.; Wagner, M.; Lerner, H.-W. An Aproach to Pin Down the Solid-State Structure of 
the “Turbo Grignard”. Organometallics 2012, 31, 1001–1005.  
18 Bao, R. L.-Y.; Zhao, R.; Shi, L. Progress and Developments in the Turbo Grignard Reagent i-
PrMgCl·LiCl: A Ten-Year Journey. Chem. Comm. 2015, 51, 6884–6900. 
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halogen exchange with the turbo Grignard reagent (Scheme 2.3). The year following 
Knochel’s initial paper, he published two reports expanding the functional group 
tolerance of his reagent. In the first report, Knochel showed that he could form Grignard 
reagents in the presence of both a triazine moiety and a simple ester, in this case an ethyl 
ester.19 While bulky esters such as tert-butyl ester were tolerated by reagents such as 
iPrMgCl, simpler esters had presented more of a challenge. In the second report, Knochel 
showed that a Grignard reagent could be formed in the presence of an electrophilic 
boronic pinacol ester.20 
 Additional work five years later demonstrated the utility of the method in the 
presence of phosphate esters. While most other examples of its application to that point 
had been in aryl systems, this magnesium-halogen exchange was shown to occur with a 
vinyl C–I bond.21 In 2009, Zhang showed that the formation of a Grignard using the turbo 
Grignard reagent could occur both in pyridine N-oxides as well as in the presence of 
substituted amides.22 While these are just a few representations of functional group 
tolerance, many more examples exist demonstrating the broad utility of the turbo 
Grignard reagent in forming new carbon–carbon bonds in the presence of sensitive 
electrophilic moieties.23 
                                                 
19 Liu, C.-Y.; Knochel, P. Preparation of Polyfunctionl Arylmagnesium Reagents Bearing a Triazene 
Moiety. A New Carbazole Synthesis. Org. Lett. 2005, 7, 2543–2546. 
20 Baron, O.; Knochel, P. Preparation and Selective Reaction of Mixed Bimetallic Aromatic and 
Heteroaromatic Boron–Magnesium Reagents. Angew. Chem. Int. Ed. 2005, 44, 3133–3135. 
21 Piller, F. M.; Bresser, T.; Fischer, M. K. R.; Knochel, P. Preparation of Functionalized Cyclic Enol 
Phosphates by Halogen-Magnesium Exchange and Directed Deprotonation Reactions. J. Org. Chem. 2010, 
75, 4365–4375. 
22 Duan, X.-F.; Ma, Z.-Q.; Zhang, F.; Zhang, Z.-B. Magnesiation of Pyridine N-Oxides via Iodine or 
Bromine-Magnesium Exchange: A Useful Tool for Functionalizing Pyridine N-Oxides. J. Org. Chem. 
2009, 74, 939–942. 
23 For further examples, see: (a) Ren, H.; Knochel, P. Regioselective Functionalization of Trisubstituted 
Pyridines Using a Bromine–Magnesium Exchange. Chem. Commun. 2006, 726–728. (b) Frischmuth, A.; 
Unsinn, A.; Groll, K.; Stadtmüller, H.; Knochel, P. Preparations and Reactions of SF5-Substituted Aryl and 




 Because the turbo Grignard reagent is so reactive, it can undergo magnesium-
halogen exchange at temperatures as low as -78 °C. This flexibility in temperature allows 
for the tuning of reactivity of the eventual Grignard reagent. Many functional groups that 
                                                                                                                                                 
F.; Krasovskiy, A.; Knochel, P. Convenient Magnesiation of Aromatic and Heterocyclic Rings Bearing a 
Hydroxy Group in Presence of LiCl. Chem. Commun. 2004, 2288–2289. (d) Kopp, F.; Wunderlich, S.; 
Knochel, P. Halogen–Magnesium Exchange on Unprotected Aromatic and Heteroaromatic Carboxylic 
Acids. Chem. Commun. 2007, 2075–2077. (e) Kopp, F.; Knochel, P. Functionalization of Unprotected 
Uracil Derivatives Using the Halogen-Magnesium Exchange. Org. Lett. 2007, 9, 1639–1641. (f) Kopp, F.; 






are not reactive with the turbo Grignard reagent at lower temperatures can act as effective 
electrophiles at higher temperatures. For example, substituted amides are non-reactive 
during Grignard formation at -60 °C, they can serve as electrophiles at higher 
temperatures.24 Though nitrile groups are well tolerated, a number of methods have been 
developed to install them using the turbo Grignard as well.24,25  
 Like traditional Grignard reagents, use of the turbo Grignard is a reliable way of 
forming carbon–carbon bonds. Of particular interest, however, is the use of the turbo 
Grignard to attack non-carbon electrophiles to form carbon–heteroatom bonds. While 
boronic esters are tolerated as functional groups, they can also be formed by using borate 
esters as electrophiles in the presence of the turbo Grignard reagent (Scheme 2.4). Both 
boronic esters26 and boronic acids27 can be generated following nucleophilic attack by the 
generated Grignard and the cleavage of a B–OR bond. In addition, a wide variety of 
electrophiles can be used to form carbon–nitrogen bonds,28 carbon–sulfur bonds,29 
carbon–phosphorus bonds,21 carbon–tin bonds,22 and carbon–halogen bonds.30 
                                                 
24 Liu, C.-Y.; Ren, H.; Knochel, P. Magnesiated Unsaturated Silylated Cyanohydrins as Synthetic 
Equivalents of Aromatic and Heterocyclic Grignard Reagents Bearing a Ketone or and Aldehyde. Org. 
Lett. 2006, 8, 617–619. 
25 Anbarasan, P.; Neumann, H.; Beller, M. A Novel and Convenient Synthesis of Benzonitriles: 
Electrophilic Cyanation of Aryl and Heteroaryl Bromides. Chem. Eur. J. 2011, 17, 4217–4222. 
26 Leermann, T.; Leroux, F. R.; Colobert, F. Highly Efficient One-Pot Access to Functionalized 
Arylboronic Acid via Noncryogenic Bromine/Magnesium Exchange. Org. Lett. 2011, 13, 4479–4481. 
27 Demory, E.; Blandin, V.; Einhorn, J.; Chavant, P. Y. Noncryogenic Preparation of Functionalized 
Arylboronic Esters through a Magnesium–Iodine Exchange with in Situ Quench. Org. Process Res. Dev. 
2011, 15, 710–716. 
28 (a) Sinha, P.; Knochel, P. Preparation of Polyfunctional Tertiary Amines via the Electrophilic Amination 
of Arylmagnesium Compounds Using N-Chloroamines. Synlett 2006, 3304-3308. (b) Frischmuth, A.; 
Unsinn, A.; Groll, K.; Stadtmüller, H.; Knochel, P. Preparations and Reactions of SF5-Substituted Aryl and 
Heteroaryl Derivatives via Mg and Zn Organometallics. Chem. Eur. J. 2012, 18, 10234–10238. 
29 (a) Krasovskiy, A.; Gavryushin, A.; Knochel, P. A General Thiolation of Magnesium Organometallics 
Using Tetramethylthiuram Disulfide. Synlett 2005, 2691–2693. (b) Reeves, J. T.; Camara, K.; Han, Z. S.; 
Xu, Y.; Lee, H.; Busacca, C. A.; Senanayake, C. H. The Reaction of Grignards Reagents with Bunte Salts: 
A Thiol-Free Synthesis of Sulfides. Org. Lett. 2014, 16, 1196–1199. 
30 (a) Despotopoulou, C.; Bauer, R. C.; Krasovskiy, A.; Mayer, P.; Stryker, J. M.; Knochel, P.  Selective 




 In summary, the Grignard reagent has emerged as a versatile strategy for not only 
forming new carbon–carbon bonds, but also forming carbon–heteroatom bonds. The 
molecular structure of iPrMgCl·LiCl allows for more facile magnesium-halogen 
exchange. This increase in reactivity allows the reaction to take place at lower 
temperatures, which allows for more reliable tuning of the reactivity of the resultant 
Grignard species. By modulating reaction temperatures, magnesium-halogen exchange 
can be achieved in the presence of a wide array of sensitive functional groups. By 
increasing the temperature, those same functional groups can act as electrophiles in the 
resulting Grignard reaction.  
                                                                                                                                                 
J. 2008, 14, 2499–2506. (b) Anbarasan, P.; Neumann, H.; Beller, M. Efficient Synthesis of Aryl Fluorides. 
Angew. Chem. Int. Ed. 2010, 49, 2219–2222. 
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2.2 Late Stage Functionalization of 1,2-Azaborines at the B-Position 
2.2.1 Nucleophilic Addition to the B-Position 
The B-position is unique amongst positions on the ring of 1,2-azaborine because 
of boron’s formally vacant p-orbital. This empty orbital causes the boron at this position 
to be susceptible to nucleophilic attack, allowing for a method of substitution that is 
completely orthogonal to functionalization at every other position of the 1,2-azaborine 
ring.31 Nucleophilic addition to the B-position has been demonstrated with several B–X 
groups present. In 2007, Liu demonstrated that a number of different carbon, oxygen, 
nitrogen, sulfur, and hydride nucleophiles could add to 1,2-azaborine 2.20 in good to 
great yields (Table 2.5). In addition to these nucleophiles, it was also shown that oxygen 
nucleophiles could be generated in situ in the presence of a base (Scheme 2.5).32 
 
                                                 
31 McConnell C. R.; Liu, S.-Y. Late-Stage Functionalization of BN-Heterocycles. Chem. Soc. Rev. 2019, 
48, 3436–3453. 
32 Marwitz, A. J. V.; Abbey, E. R.; Jenkins, J. T.; Zakharov, L. N.; Liu, S.-Y. Diversity through Isosterism:  




 In addition to the B-Cl-1,2-azaborine, 1,2-dihydro-1,2-azaborine also served as a 
competent substrate for nucleophilic addition.33 It was found that the protic N–H bond 
was attacked by the nucleophilic/basic partner in the reaction. A second equivalent of 
nucleophile was necessary to first deprotonate the N–H, which could then be regenerated 
with subsequent addition of a proton source (Table 2.6).  
 
 Similar attempts to perform a nucleophilic attack on 2.25 were relatively more 
challenging. While it was possible to replace the B–OR bond with strong nucleophiles 
                                                 
33 Lamm, A. N.; Garner III, E. B.; Dixon, D. A.; Liu, S.-Y. Nucleophilic Aromatic Substitution of 1,2-
Dihydro-1,2-Azaborines. Angew. Chem. Int. Ed.  2011, 50, 8157–8160. 
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such as simple organolithiates or Grignard reagents, weaker nucleophiles were unable to 
add to the B-position. However, B–Cl could be regenerated in situ from B–OR bonds in 
the presence of BCl3. Intermediate 2.26 could then undergo a subsequent nucleophilic 
addition to form products 2.27-2.29.34 In summary, B–Cl, B–H, and B–OR bonds have 
all proven suitable substrates for nucleophilic addition. 
 
2.2.2 Non-Nucleophilic Activation of the B–R and B–X Bond 
While nucleophilic addition to the B-position is a reliable method for adding 
chemical diversity to the core of 1,2-azaborines, other metal mediated methods can be 
used to either add sensitive functionality or break more stable B–C bonds. In 2013, a 
rhodium-catalyzed arylation of B–Cl substituted 1,2-azaborines was reported by the Liu 
                                                 
34 Abbey, E. R.; Lamm, A. N.; Baggett, A. W.; Zakharov, L. N.; Liu, S.-Y. Protecting Group-Free 
Synthesis of 1,2-Azaborines: A Simple Approach to the Construction of BN-Benzenoids. J. Am. Chem. 
Soc. 2013, 135, 12908–12913. 
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group.35 This cross-coupling takes place via sequential transmetalations with the 
azaborine and an arylstannane. Mechanistic studies suggest that the arylstannane first 
transfers its arene from the tin to the rhodium, followed by transfer of the aryl group to 
the 1,2-azaborine. A number of functional groups, such as esters, nitriles, and aldehydes, 
which are generally too sensitive to be tolerated by nucleophilic Grignard reagents or 
organolithiates can be coupled to 1,2-azaborines using this method (Scheme 2.7). 
 
 In addition to B–Cl activation, B–H activation was also demonstrated in a 
separate rhodium-catalyzed synthesis of BN isosteres of stilbene.36 A potential 
                                                 
35 Rudebusch, G. E.; Zakharov, L. N.; Liu, S.-Y. Rhodium-Catalyzed Boron Arylation of 1,2-Azaborines. 
Angew. Chem. Int. Ed. 2013, 52, 9316–9319. 
36 Brown, A. N.; Zakharov, L. N.; Mikulas, T.; Dixon, D. A.; Liu, S.-Y. Rhodium-Catalyzed B–H 




mechanism included oxidative addition of the B–H bond to the rhodium catalyst followed 
by a β-migratory insertion of the styrene coupling partner. Subsequent β-hydride 
elimination would yield the BN stilbene product and a rhodium dihydride complex. This 
rhodium dihydride complex can hydrogenate a second styrene coupling partner to 
regenerate the active catalyst, consistent with the need for two equivalents of styrene. 





 While it has been shown that B–H, B–Cl, and B–OR bonds are readily 
modifiable, B–C bonds, in particular aryl groups, are far more robust,31 and their removal 
is not trivial. A recent report from the Liu group details a copper-mediated oxidation of 
alkyl and aryl B–C bonds.37 An alkoxy group first adds to the B-position in the presence 
of a stoichiometric oxidant, forming a tetracoordinate boron species. Either a Cu(I) or 
Cu(II) compound then promotes homolytic cleavage of the B–C bond, regenerating a 
tricoordinate boron species. This yields a B–OR substituted 1,2-azaborine, which is easily 
modifiable by methods previously described. Alkyl substituted 1,2-azaborines proceeded 
with good to great yields, while aryl substituted 1,2-azaborines proceeded with modest 
yields (Scheme 2.9). 
  
                                                 
37 Bagget, A. W.; Liu, S.-Y. A Boron Protecting Group Strategy for 1,2-Azaborines. J. Am. Chem. Soc. 
2017, 139, 15259–15264. 
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2.3 Development of a Functional Group Tolerant B–Aryl Nucleophilic 
Substitution Method 
2.3.1 Biaryl Molecules as a Privileged Class in Medicinal Chemistry 
A privileged structure in medicinal chemistry is defined as “a single molecular 
framework able to provide ligands for diverse receptors.”38 Biaryl compounds are one 
example of a privileged motif, as they have been shown to bind to a wide range of protein 
receptors across a number of different therapeutic areas.39 Because of the privileged 
status of biaryl compounds, and as 1,2-azaborine is an isostere of benzene, we believe 
biaryl compounds are an attractive synthetic target for exploring the biological effects of 
BN-CC isosterism. Additionally, aryl substitution at the B-position affords enhanced 
oxidative stability to 1,2-azaborines. 
As previously discussed, we have developed two general methods of adding 
arenes at the 2-position: nucleophilic addition or a rhodium-catalyzed boron arylation. 
These methods both have shortcomings that limit their usefulness in preparing drug like 
molecules. In the case of Grignard and lithiate reactions, we are unable to add sensitive 
electrophilic moieties such as carbonyl or nitrile containing arenes to 1,2-azaborine. 
While the rhodium-catalyzed method can tolerate these groups, it requires stoichiometric 
amounts of toxic organotin reagents. To increase the scope of sensitive aryl functional 
groups that can be added to the B-position of 1,2-azaborine while obviating the need for 
toxic heavy metal reagents, a LiCl mediated Grignard-type reaction developed by 
Knochel16 has been adapted to use with N-TBS-B-Cl-1,2-azaborines.  
                                                 
38 Horton, D. A.; Bourne, G. T.; Smythe, M. L. The Combinatorial Synthesis of Bicyclic Privileged 
Structures or Privileged Substructures. Chem. Rev. 2003, 103, 893–930 
39 Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged Molecules for Protein Binding 
Identified from NMR-Based Screening. J. Med. Chem. 2000, 43, 3443–3447. 
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2.3.2 Adapting the Turbo Grignard Reaction to 1,2-Azaborines 
The procedure for the turbo Grignard reaction was adapted directly from 
Knochel’s 2004 report16 and was used with the commercially available N-TBS-B-Cl-1,2-
azaborine (2.33). The two initial addition partners chosen were para-iodo-benzonitrile 
and meta-iodo-bromobenzene, both of which were effective in moderate yields (Scheme 
2.10). The reaction was also attempted without the presence of the copper catalyst, 
though no desired product was observed. 
 
These reaction conditions were then attempted with a halogenated 1,2-azaborine 
(2.36) and an ester bearing aryl addition partner (2.37). This protected phenyl ester has 
been used as a synthetic precursor to a number of BN isosteres of biologically active 
molecules.40 Previously, however, this group had to be installed using the rhodium-
catalyzed cross coupling method that required stoichiometric amounts of organotin 
reagents. We have demonstrated that this same functionality can be installed onto the 
azaborine core using the turbo Grignard reaction in comparable yields (Scheme 2.11). 
                                                 
40 Zhao, P.; Nettleton, D. O.; Karki, R. G.; Zécri, F. J; Liu, S.-Y. Medicinal Chemistry Profiling of 




 Having demonstrated the utility of the turbo Grignard reaction with B–Cl bearing 
1,2-azaborines, we attempted to apply the reaction to 1,2-azaborines that contained B–O 
bonds. Attempts were made to apply this reaction to our tetra-substituted 1,2-azaborine 
2.3941. Unfortunately, direct application of the turbo Grignard reaction conditions was 
unsuccessful. Additionally, deprotonation of the group and an attempted ligand exchange 
with BCl3 also did not yield product (Scheme 2.12). 
 
                                                 
41 See section 1.3.3 Synthesis of N-TBS-B-OH-3-Br-5-I-1,2-azaborine 
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 To demonstrate that this method could be applied to B–OR systems, the reaction 
was attempted with 2.41, which is the synthetic precursor of 2.39,41 as a substrate and 
2.40 as the addition partner. As has been previously reported,34 a comproportionation 
reaction generated 2.42 in situ. 2.42 was then isolated and subjected to turbo Grignard 





While the current scope of the turbo Grignard reaction with 1,2-azaborines is 
limited, it demonstrates a clear ability to tolerate sensitive electrophilic groups, including 
esters and nitriles, that previously could only be installed with rhodium-catalyzed cross-
coupling. We have shown that it can be effective with both B–Cl and B–OR substituted 
1,2-azaborines. Additionally, we have shown that halogenation on the 1,2-azaborine core 
does not inhibit this reaction.  
Our ultimate goal for this chemistry is to develop a tetra-orthogonally reactive 
azaborine in order to study the effects of BN-CC isosterism of 1,2-azaborines in 
biological settings. In order to achieve this, we must be able to synthesize complex 
isosteres of biologically active molecules. Application of the turbo Grignard reaction 
demonstrates that sensitive aryl groups can be installed on the core of 1,2-azaborines in a 




2.5.1 General Considerations 
Unless otherwise noted, all oxygen- and moisture-sensitive manipulations were 
carried out in flame- or oven-dried glassware under an atmosphere of nitrogen using 
either standard Schlenk technique or a nitrogen-filled glove box. THF, CH2Cl2, and 
pentane were dried using a Brady® solvent purification system, which consisted of 
columnar molecular sieves under argon atmosphere. All column chromatography was 
performed by hand in a nitrogen-filled glove box. Silica gel (230-400 mesh) was dried for 
18 hours at 240 ºC under high vacuum. All reagents were purchased from commercial 
vendors (Acros Organics®, Millipore Sigma®, TCI®) and used as received unless 
otherwise noted.  
All NMR spectra were recorded on a Varian VNMRS 500 MHz, Varian VNMRS 
600 MHz, or INOVA 500 MHz spectrometer at ambient temperature in the Michael 
Gerson Magnetic Resonance and Instrumentation Laboratory at Boston College. 11B 
NMR spectra were externally referenced to BF3·Et2O (δ 0.0 ppm). 1H NMR spectra were 
internally referenced to chloroform-d3 (δ 7.26 ppm) or benzene-d6 (δ 7.16). Infrared 
spectroscopy was performed on a Bruker ALPHA-Platinum FT-IR Spectrometer with an 
ATR-sampling module. High-resolution mass spectrometry analysis was performed by 
Marek Domin on a JEOL AccuTOF instrument equipped with a DART ion source in 
positive ion mode at the Boston College Center for Mass Spectrometry.  
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2.5.2 Addition of Turbo Grignard Reagents to 1,2-Azaborines 
4-iodobenzoic acid (1.80 g, 7.26 mmol), 2-
trimethylsilylethanol (3.12 mL, 21.77 mmol), and N,N-
dimethylaminopyridine (88.66 mg, 0.725 mmol) were 
dissolved in 45 mL of CH2Cl2 in a 250 mL roundbottom flask and allowed to stir at 0 °C 
under ambient atmosphere. While stirring, liquid N,N-dicyclohexylcarbodiimine (1.65 g, 
7.98 mmol) was slowly added to the solution, which was allowed to warm to 24 °C while 
stirring over 4 hours. As the reaction progressed, a solid, white precipitate was observed 
in the reaction mixture. At the conclusion of the reaction, the crude reaction mixture was 
passed through a glass fritted funnel and the filtrate was concentrated in vacuo. 2.37 was 
purified via silica gel chromatography (1:3 dichloromethane in pentane) and collected as 
a salmon colored liquid (2.13 g, 84.3% yield). Spectra of isolated compound matched 
previously published records.42  
                                                 
42 Mallagaray, A.; Canales, A.; Domínguez, G.; Pérez-Castells, J.; Jiménez-Barbero, J. Rigid Lanthanide 
Binding Tag for NMR 3D Structure Determination of Carbohydrates. Chem. Comm. 2011, 47, 7179–7181. 
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A dry 20 mL glass vial flushed with nitrogen was filled with a 
solution of iPrMgCl·LiCl in tetrahydrofuran (0.535 mL, 0.862 M, 
0.461 mmol) and cooled to –15 °C. para-Iodo-benzonitrile (101 mg, 
0.439 mmol) was dissolved in 2 mL of THF and slowly added to the 
flask. After allowing to stir for 30 minutes, 2.33 (100 mg, 0.439 mmol) was dissolved in 
2 mL of THF and added dropwise to the flask, followed by Cu(I)CN·(LiCl)2 in 
THF (0.110 mL, 0.110 mmol, 1.00 M). The reaction was allowed to stir for 12 hours as it 
warmed to 24 °C. At the conclusion of the reaction, the crude reaction mixture was 
concentrated in vacuo and dissolved in 2 mL of a 2:1 pentane/dichloromethane mixture 
and purified via silica gel chromatography (5-20% dichloromethane in pentane). 2.34 was 
collected as a white solid (60.5 mg, 46.8% yield). 
1H NMR (500 MHz, C6D6) δ 7.50 (dd, J = 6.5, 11.5 Hz, 1H), δ 7.15 (d, J = 7.5, 1H), δ 
7.04 (m, 4H), δ 6.71 (d, J = 11 Hz) δ 6.26 (t, J = 6.5, 1H), δ 0.96 (s, 9H), δ 0.57 (s, 6H); 
13C NMR (150 MHz, C6D6) δ 143.44, 137.78, 132.20, 129.95, 119.01, 112.50, 110.87 
26.33, 18.45, -2.54 (two Cs bonded to B was not observed); 11B NMR (160 MHz, C6D6) 
δ 38.252; FTIR (thin film) ῦ = 2956, 2930, 2886, 2858, 2226, 1603, 1504, 1453, 1389, 
1265, 1096, 998, 957, 810, 562; HRMS (DART+) calculated for C17H24BN2Si (M+): 
295.17963, observed: 295.18024.  
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A dry 20 mL glass vial flushed with nitrogen was filled with a 
solution of iPrMgCl·LiCl in tetrahydrofuran (0.535 mL, 0.862 M 
0.461 mmol) and cooled to –15 °C. 2.40 (124 mg, 0.439 mmol) was 
dissolved in 2 mL of THF and slowly added to the flask. After allowing to stir for 30 
minutes, 2.33 (100 mg, 0.439 mmol) was dissolved in 2 mL of THF and added dropwise 
to the flask, followed by Cu(I)CN·(LiCl)2 in THF (0.110 mL, 0.110 mmol, 1.00 M). The 
reaction was allowed to stir for 12 hours as it warmed to 24 °C. At the conclusion of the 
reaction, the crude reaction mixture was concentrated in vacuo and dissolved in 2 mL of a 
2:1 pentane/dichloromethane mixture and purified via silica gel chromatography (15-30% 
dichloromethane in pentane). 2.35 was collected as an orange solid (95.5 mg, 62.4% 
yield). 
1H NMR (500 MHz, C6D6) δ 7.62 (s, 1H) δ 7.50 (dd, J = 6.0, 10.5 Hz, 11.5 Hz, 1H), δ 
7.29 (d, J = 8.5 Hz, 1H) δ 7.19 (d, J = 7.5, 1H), δ 7.17 (d, J = 7.0 Hz, 1H), δ 6.83 (m, 
2H), δ 6.26 (t, J = 7.0, 1H), δ 0.70 (s, 9H), δ -0.16 (s, 6H); 13C NMR (150 MHz, C6D6) δ 
143.26, 137.80, 134.97, 130.33, 129.65, 128.58, 121.83, 112.30, 26.43, 18.54, -2.46 (two 
Cs bonded to B was not observed); 11B NMR (160 MHz, C6D6) δ 38.349; FTIR (thin 
film) ῦ = 3612, 2953, 2928, 2884, 2857, 1606, 1585, 1389, 1346, 1256, 1209, 1015, 810, 




A dry 50 mL roundbottom flask flushed with nitrogen 
was filled with iPrMgCl·LiCl in THF (0.230 mL, 0.743 
M, 0.171 mmol) and cooled to –15 °C. 2.37 (56.81 mg, 
163 umol) was dissolved in 0.5 mL of THF and slowly 
added to the flask.. After allowing to stir for 20 minutes, 2.36 (50 mg, 163 umol) was 
dissolved in 0.5 mL of THF and added dropwise to the flask, followed 
by Cu(I)CN·(LiCl)2 in THF (0.55 mL, 0.55 mmol, 1.00 M). The reaction was allowed to 
stir for 1 hour at 0 °C. At the conclusion of the reaction, the crude reaction mixture was 
concentrated in vacuo and dissolved in 2 mL of a 2:1 pentane/dichloromethane mixture 
and purified via silica gel chromatography (25-50% dichloromethane in pentane). 2.38 
was collected as an off-white solid (23.0 mg, 28.6% yield). 
 1H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 6.5 Hz, 2H) δ 7.95 (d, J = 7.5 Hz, 1H) δ 7.43 
(m, 3H), δ 6.36 (t, J = 7.0, 1H), δ 0.89 (s, 9H), δ 0.09 (s, 12H) δ 0.16 (s, 6H); 13C NMR 
(125 MHz, CDCl3) δ 167.19, 145.03, 137.81, 132.21, 129.48, 127.86, 112.15, 63.03, 
26.72, 18.88, 17.50, -1.45, -2.12 (two Cs bonded to B was not observed); 11B NMR (160 
MHz, CDCl3) δ 37.607; FTIR (thin film) ῦ = 2955, 2930, 2886, 2858, 2226, 1712, 1602, 
1504, 1453, 1389, 1271, 1096, 997, 823, 747; HRMS (DART+) calculated for 
C22H35BNO2Si2Br (M+): 491.14773, observed: 491.14938.  
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2.41 (200.0 mg, 0.662 mmol) was dissolved in 2 mL of CH2Cl2  in a 
dry 20 mL vial and allowed to stir under nitrogen at room 
temperature. BCl3 in hexanes (728 µL, 1.0 M, 0.728 mmol) was 
added dropwise to the vial and allowed to stir for 3 hours. The crude 
reaction mixture was concentrated in vacuo and redissolved in pentane, which was then 
passed through a PTFE filter. The pentane filtrate was again concentrated in vacuo and 
redissolved in 3 mL of THF. A dry 25 mL roundbottom flask flushed with nitrogen was 
filled with iPrMgCl·LiCl in THF (0.806 mL, 0.862 M, 695 µmol) and cooled to –15 
°C. 2.40 (187 mg, 662 umol) in was dissolved in 3 mL of THF and was slowly added to 
the flask. After allowing to stir for 30 minutes, the solution containing isolated 2.42 was 
added dropwise to the flask, followed by Cu(I)CN·(LiCl)2 (165 uL, 165 umol, 1M in 
THF). The reaction was allowed to warm to room temperature while stirring for 12.5 
hours. At the conclusion of the reaction, the reaction mixture was concentrated in vacuo 
and purified via silica gel chromatography (5-15% dichloromethane in pentane). 2.43 was 
collected as an off-white solid (155.8 mg, 55.1% yield). 
1H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 7.5 Hz, 1H) δ 7.47 (m, 2H), δ 7.42 (d, J = 7.0 
Hz, 1H) δ  7.28 (d, J = 7.5, 1H) δ 7.22 (t, J = 7.5, 1H), δ 6.35 (t, J = 7.0, 1H), δ 0.90 (s, 
9H), δ 0.04 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 145.11, 137.85, 134.99, 130.75, 
130.26, 128.72, 121.73, 112.19, 26.17, 18.92, -2.13 (two Cs bonded to B was not 
observed); 11B NMR (160 MHz, CDCl3) δ 37.412; FTIR (thin film) ῦ = 2956, 2930, 
2885, 2858, 1601, 1550, 1471, 1337, 1265, 1110, 996, 841, 811, 758, 699, 623, 412; 
HRMS (DART+) calculated for C16H22BNSiBr2 (M+): 428.06470, observed: 428.00260.  
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2.5.3 Spectral Data 
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